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Ahx 6-aminohexanoic acid moiety  
ARC conjugate of a heterocyclic fragment and a peptide or pep-
tide analogue 
ARC-Fluo ARC-probe labeled with a fluorescent dye 
ARC-inhibitor ARC-based inhibitor 
ARC-Lum ARC-probe possessing protein-induced signal with micro-
second-scale lifetime 
ARC-Lum(–) ARC-Lum probe lacking a fluorescent dye 
ARC-Lum(Fluo) ARC-Lum probe incorporating a fluorescent dye 
ARC-Lumi4Tb ARC-probe incorporating terbium cryptate Lumi4Tb 
ARC-PF647 ARC-probe incorporating PromoFluor-647 dye 
ARC-Photo ARC-probe incorporating a photoluminescent label 
ARC-probe ARC-based inhibitor possessing luminescent properties  
ARC-TAMRA ARC-probe incorporating 5-TAMRA dye 
ATP adenosine 5’-triphosphate 
avGFP green fluorescent protein from the jelly fish Aequorea 
victoria 
BRET bioluminescence resonance energy transfer 
cAMP cyclic adenosine 3’,5’-monophosphate 
CK2α catalytic subunit of protein kinase CK2, subtype α 
CYP cyan fluorescent protein 
EGFP enhanced green fluorescent protein 
FA fluorescence anisotropy 
FI fluorescence intensity 
FITC fluorescein isothiocyanate  
FP fluorescent protein 
FRET Förster-type resonant energy transfer 
GFP green fluorescent protein 
GOI gene of interest 
His6  hexa-histidine 
HTS high-throughput screening 
IC50 concentration of inhibitor that causes 50% reduction of 
enzymatic/catalytic activity of the enzyme in the assay 
conditions  
KD equilibrium dissociation constant determined from direct 
binding assay 
Kd equilibrium dissociation constant determined from dis-
placement assay 
Ki equilibrium dissociation constant determined from inhibi-
tion assay 




PK protein kinase 
PKA cAMP-dependent protein kinase A or protein kinase A 
PKAc catalytic subunit of PKA 
PKAr regulatory subunit of PKA 
POI protein of interest 
QY quantum yield 
RFP red fluorescent protein 
TAMRA 5-carboxytetramethylrhodamine 
TGL time-gated luminescence 
TR time-resolved 
TRF  time-resolved fluorescence 
UV ultra-violet 







Phosphorylation reaction is an important post-translational protein modification 
procedure in cells, which is carried out by protein kinases (PKs). This modifi-
cation leads to increase in the diversity of the proteome that influences various 
aspects of normal and pathological physiology. Dysregulation of protein phos-
phorylation balances, caused by the aberrant activity of PKs is a cause or conse-
quence of several complex diseases such as cancers, inflammatory disorders, 
cardio-vascular diseases and diabetes [1]. Therefore PKs have become im-
portant drug targets in the 21st century [2]. In recent 15 years, 30 small-mole-
cule PK inhibitors have been approved for use in clinical practice [3]. 
More than 500 PKs, constituting almost 2.5 % proteins coded by the human 
genome, are carrying out the phosphorylation of various proteins [4]. In addi-
tion to being a potential drug targets, PKs also serve as biomarkers for cancers 
and other diseases, as altered expression level of various PKs is observed in a 
variety of malignancies [5]. Thus there is high demand for analytical methods 
that enable determination of expression and activity levels of specific PKs in 
clinical samples, such as bodily fluids and cancerous tissues. Thus high 
throughput assays for screening PK inhibitors also form an important compo-
nent of drug development pipeline. 
During the last decade, it has been understood that merging of two disci-
plines, synthetic chemistry and protein engineering, is needed to construct mol-
ecules and their complexes with new functionalities that can create novel op-
portunities for biomedical research, drug development and disease diagnostics 
[6, 7].  
In this thesis combination of chemical and genetic approaches was used for 
the development of analytical tools for the characterization of PKs and PK in-
hibitors. PKs (PKAc, CK2α, and PIM kinases) were fused with fluorescent 
proteins (FPs). On the other hand, ARC-based small-molecule PK inhibitors 
were developed into protein binding-responsive ARC-Lum probes possessing 
unique photoluminescent properties. Joint application of PKs fused with fluo-
rescent proteins and ARC-Lum probes enabled the construction of sensor sys-
tems that can be used for specific and sensitive determination of PKs in biologi-






1. Protein kinases 
The protein phosphorylation plays a crucial role in intercellular communication 
during development, in physiological responses and in homeostasis, and in the 
functioning of the nervous and immune systems. Phosphorylation has been 
found to be a common post-translational modification with 500,000 potential 
phosphorylation sites in the human proteome and 25,000 phosphorylation 
events described for 7000 human proteins [8]. Protein phosphorylation is car-
ried out by PKs which belong to the transferase class of enzymes. PKs associate 
with a substrate protein and a nucleoside triphosphate [usually adenosine  
5’-triphosphate (ATP)] and transfer the γ-phosphoryl group of the latter to 
specific amino acid residues, such as serine, threonine and tyrosine of the 
substrate proteins. PKs mediate most of the signal transduction cascades in cells 
by modifying of substrate protein activity. PKs also control many cellular 
processes, such as metabolism, transcription, cell cycle progression, differen-
tiation, and apoptosis [9].  
In 2002, Manning et al. [9], classified the PK complement of human genome 
(kinome) into nine groups of PKs based on the phylogenetic analysis [1]. They 
reported 518 PKs, comprising of 478 genes and 40 atypical genes. However, a 
very simple way for classification of PKs is based on the target amino acid on 
the substrate protein which is phosphorylated by the PK. During the course of 
phosphorylation, the phosphate group from the nucleotide is transferred to the 
side chain of an amino acid of the substrate protein. The human PKs phosphor-
ylates, hydroxyl group of the side chain of the amino acids of a target protein, 
follows O-phosphorylation. However, N-phosphorylation of residues with 
amine-containing side chains (histidine, lysine, and arginine) are not prevalent 
in human kinome [10]. These phosphorylated residues are asymmetrically 
distributed (85% serine, 11.8% threonine, and 1.8% tyrosine residues) [4]. 
Based on the phosphorylatable residue PKs can be classified as follows,  
 Serine/Threonine kinases: catalyze the phosphorylation of the hydroxyl 
group of serine or threonine in the substrate protein (e.g., AGC kinases, 
CAMK kinases, etc.) 
 Tyrosine kinases: catalyze the phosphorylation of the hydroxyl group of 
tyrosine in the substrates protein (e.g., ABL kinases, SRC kinases, etc.) 
 Dual specific kinases: can act as both serine/threonine and tyrosine ki-
nases (e.g., MAPK) 
 
PKs recognize certain consensus sequence surrounding the phosphorylatable 
residue of the substrate protein and specifically carry out the phosphorylation 
reactions. Thus, based on the substrate consensus sequences or the specificity 
determinants, the serine/threonine kinases can be classified into three categories 
[11],  
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 Basophilic PKs, prefer basic and hydrophobic amino acids as the determi-
nants; majority of PKs of the AGC group and some CAMK group of PKs 
belong to this category; 
 Proline-directed PKs, prefer basic amino acids in substrate recognition 
sequence but additionally require a proline residue at position P+1; mem-
bers of CMGC group fall in this category; 
 Acidophilic/phosphate-directed PKs, comprise carboxylic acids and phos-
phorylated residues in their consensus sequence.  
 
 
1.1. Basophilic kinases 
Basic amino acids arginine and lysine serve as the specificity determinants for 
PKs that belong to this category, they target serine and threonine residues of 
substrate protein surrounded by arginine and lysine residues. PKs PKA, PKB, 
PKC, PKG, ROCK, PIM, MSK, etc. belong to this category [12]. 
Protein kinase A (PKA) or cAMP-dependent protein kinase was first char-
acterized in 1968 and its mechanism of action well understood, thus it serves as 
the proto-type kinase for the study of other PKs [13]. PKA was the first PK 
whose crystal structure was solved already in 1991 [14]. PKA holoenzyme exits 
as an inactive tetramer composed of two catalytic subunits (PKAc) and a dimer 
of regulatory subunits (PKAr). The activity of PKA is controlled by cyclic 
adenosine 3’,5’-monophosphate (cAMP), which is produced by cyclisation of 
ATP, catalyzed by adenylyl cyclases. On the other hand, cAMP is degraded by 
phosphodiesterase. The activity of adenylyl cyclase is controlled by G-protein 
coupled receptors which are responding to external stimuli or by direct activa-
tors such as forskolin. When adenylyl cyclase is activated, its triggers the con-
version of ATP to cAMP. The PKA tetramer is dismantled in response to the 
elevation of cAMP concentration in cells. Two molecules of cAMP bound to 
each of the PKAr subunits leading to the release PKAc subunits. Then PKAc 
subunit catalyzes the phosphorylation of the target proteins.  
Though PKA has been suggested to participate in the genesis and progres-
sion of various tumors [15], the knowledge about its ubiquitous expression and 
hundreds of established substrate proteins [12] has reduced its potential as a 
drug target. Still, a novel oral ATP-competitive multi-AGC kinase inhibitor 
(also inhibiting PKAc) AT13148 has been taken to clinical trials as a cancer 
drug candidate [16]. Only recently, it has been established that a mutation 
(L205R) in PKAc abolishes the binding of PKAc to PKAr and the resulting 
increased catalytic activity of PKAc is associated with the onset of cortisol-
secreting adrenocortical adenomas [17–19]. Thus, there is a potential option for 
the development of drugs based on inhibitors that are specifically targeting the 
mutated form of PKAc. 
Three constitutively active PKs PIM1, PIM2, and PIM3 form an important 
family (PIM kinases, possessing highly similar kinase domain with 60% ho-
mology) of basophilic serine/threonine kinases [20]. The PIM family of kinases 
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are named for their mode of discovery as proviral common integration sites in 
moloney murine leukemia virus-induced lymphomas. PIM kinases belong to the 
calcium⁄calmodulin-dependent (CAMK) group of PKs. Although all PKs of the 
PIM family participate in regulation of key biological processes, such as cell 
proliferation, differentiation, survival, and apoptosis, their relative expression 
level can be vary in cells of different origin and the expression level depends on 
the physiological conditions [21, 22]. PIM kinases lack obvious regulatory do-
mains, the regulation of their activity occurs at the level of transcription, trans-
lation, and degradation [23]. Overexpression of PIM kinases has been found in 
human myeloid and T-cell leukemias and lymphomas, but also in numerous 
solid tumors (e.g., pancreatic and prostate cancers, non-small-cell lung cancer, 
squamous cell carcinoma, gastric carcinoma, liver carcinoma, liposarcoma, etc.) 
[24]. Different isoforms of PIM kinases have been observed in cells, these 
isoforms are encoded from the PIM gene by alternate translation initiation co-
don. For example, in mice and humans, a single PIM2 transcript gives rise to 
three isoforms of the protein (MWs of 34, 37, and 40 kDa) that share an identi-
cal catalytic site but differ at their N-termini, due to in-frame alternative trans-
lation initiation sites [25]. In leukemic cells, the three PIM2 isoforms have very 
short half-lives, thereby the longest isoform is significantly more stable than the 
shorter isoforms [26]. 
High expression level of PIM2 isozyme of the PIM family has been reported 
for several hematologic malignancies [24]. For example, increased expression 
of the human PIM2 is observed in chronic lymphocytic leukemia and non-
Hodgkin lymphomas. PIM2 also known to promote the cell survival and inhibit 
programmed cell death [27]. Therefore, in addition to being a potential drug 
target for hematologic malignancies, PIM2 kinase is also of interest as 
biomarkers for diagnosis of these diseases [21].  
 
 
1.2. Acidophilic kinases 
Acidophilic PKs phosphorylate serine/threonine residues flanked by acidic 
amino acids such as aspartic acid and glutamic acid [28]. Protein kinase CK2 
(the acronym being derived from the misnomer “casein kinase 2”) is a ubiqui-
tous acidophilic kinase which effectively contributes to the human phospho-
proteome [29]. 
PK CK2 is a highly conserved acidophilic serine/threonine protein kinase 
ubiquitously expressed in all eukaryotic cells [30]. CK2 is a pleotropic PK that 
is known to phosphorylate more than 300 substrates, it effectively uses both 
ATP and Guanosine-5'-triphosphate (GTP) as phosphate donors. A consensus 
sequence for CK2 catalyzed phosphorylation contains acidic amino acids 
(Ser/Thr-X-X-Glu/Asp/pSer) [31]. CK2 may also be a dual-specific kinase that 
can also phosphorylate tyrosine in some special cases [32].  
CK2 is a tetramer composed of two catalytic (α and α´) and two regulatory 
(β) subunits. The catalytic subunits, CK2α (MW = 42–44 kDa) and CK2α′  
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(MW = 38 kDa), are products of individual genes in mammals with more than 
90% sequence identity in their N-terminal 330 amino acids, and entirely unre-
lated C-termini. A third catalytic isoform, CK2α´´ is also found in human cells. 
CK2α´´ is practically identical to CK2α, except for the last 32 amino acids of its 
C-terminus. However the regulatory CK2β subunit (25 kDa) has no extensive 
similarity to other proteins [33]. In contrast to many signaling PKs, CK2 is 
constitutively active, independent of second messengers or phosphorylation 
events, and the mechanism of regulation of CK2 activity in cells is still unclear [34]. 
A large number of substrates which are involved in gene expression and cell 
growth are phosphorylated by CK2. The expression level of CK2 has been 
found to be upregulated in many of the cancers. Overexpression of CK2 has 
been reported in several inflammatory diseases, cardio-vascular disorders and 





Due to their high sensitivity and productivity photoluminescence-based tech-
niques form the basis of many research tools used for high throughput bio-
chemical assays, live cell imaging and luminescence-based sensors for analysis 
of proteins in complex biological solutions such as bodily fluids and cell lysates 
etc. Luminescence is the generic term for the emission of light and generally 
divided as fluorescence and phosphorescence (luminescence does not include 
emission of light that occurs from substances heated to high temperature). The 
luminescence arising from direct photoexcitation of the emitting species is 
called photoluminescence [36].  
So, the radiative emission of photon from excited energy level to ground 
level is called as photoluminescence. When a molecule is excited to higher 
energy level (singlet state, S1 or S2) by absorbing a photon, it returns to the 
ground state (S0) by emitting a photon or by internal conversion (Figure 1). In 
case of fluorescence, the excited molecule returns to the ground state from the 
singlet excited state by emitting a photon. The energy of the emitted photon is 
less compared to that of the absorbed photon, thus the emission results in longer 
wavelength. The difference between the positions of band maxima of the ab-
sorption and emission spectra is called the Stokes shift. Several other relaxation 
process compete with fluorescence emission such as non-radiate dissipation of 
energy as heat, and energy transfer to other molecule (quenching) and intersys-
tem crossing. During the intersystem crossing, the excited molecule goes to first 
excited triplet state (T1) and then returns to the ground singlet state by emitting 
a photon, the phenomenon is called phosphorescence. The transition of excited 
molecule from S1 to T1 state is a forbidden process. Usually luminophores com-
prising of heavy atoms facilitate this process [37]. Typically phosphorescence 





Figure 1. A simplified Jablonski diagram for photoluminescence, adopted from [37]. 
When a luminophore absorbs light, it is excited from its ground state (S0) to excited 
state (S1 and S2). The molecule can rapidly relax to the lowest vibrational level of the 
lowest excited state by vibrational rotation (VR). By internal conversion (IC), the mole-
cule can relax to S1 from S2. The molecule then returns to ground state by emitting en-
ergy as fluorescence or by IC. Additionally, molecules in S1 state can undergo a spin 
conversion to first excited triplet state (T1) via intersystem crossing (ISC) and then re-
laxes to ground state by phosphorescence.  
 
 
The average lifetime that a molecule spends in the excited state before returning 
to the ground state is called luminescence lifetime. The ratio between the num-
ber of emitted and absorbed photons is called as the quantum yield (QY). Lu-
minophores possessing high quantum yield, display brighter emission. Thus the 
brightness of a luminophore is the product of its molar absorption coefficient (ε) 
and QY. The QY of the fluorophore is related to the processes that compete 
with fluorescence for depopulation of the excited state. Therefore, the fluores-
cence intensity (FI) depends on the initial population of excited state multiplied 
by QY [38].  
In general photoluminescence-based measurement can be performed either 
in steady-state or time-resolved (TR) mode. In case of steady-state measurement 
the sample is illuminated with continuous beam of light or pulses of light and 
the emission is recorded simultaneously. As the fluorescence decay is very 
quick, in fluorescence-based measurements the steady-state is reached almost 
immediately. In case of TR measurements, the sample is exposed to pulse of 
light, whereas the pulse width is shorter than the decay time of the luminophore 
[37]. In case of complex samples, such as live cell assays and cell lysates, TR 
measurements are advantageous as the background autofluorescence that arises 
from the cellular components can be avoided.  
Photoluminescence-based detection measures changes in the luminescence 
parameters such FI or luminescence intensity, fluorescence anisotropy/ 
polarization (FA) and luminescence lifetime of a luminophore.  
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2.1. Förster-type resonant energy transfer 
Förster-type resonant energy transfer (FRET, also used as Förster resonance 
energy transfer) is a non-radiate distance-dependent energy transfer from a 
donor molecule to an acceptor molecule provided that the emission spectrum of 
the donor luminophore overlaps with the absorption spectrum of the acceptor 
luminophore and these luminophores are positioned in closer proximity [39]. 
The FRET does not involve emission of light from the donor, rather the donor 
and acceptor are coupled by dipole–dipole interaction. The resonance energy 
transfer from excited state of donor, 1D* to the excited state, 1A* of acceptor 
molecule, results in the decreased luminescence lifetime and intensity of the 
donor luminophore. At the same time, the sensitized emission of the acceptor 
molecule occurs that leads to increase in the emission intensity of the acceptor.  
The FRET is dependent on many criteria, such as the distance between the 
donor and acceptor molecules, the spectral overlap between the emission spec-
trum of donor and the absorption spectrum of acceptor. The efficiency (E) and 
the rate of energy transfer [KT(r)] are related by the following equations, 
  
 ( ) = ( )  (Equation 1) 
 
 = 	  (Equation 2) 
 
where, r is the actual distance between donor and acceptor, τD is the decay time 
of donor in the absence of acceptor, and R0 is the Förster distance at which the 
energy transfer is 50%.  
The Förster distance depends on a number of factors, including the fluores-
cence QY of donor, refractive index of the solution and the spectral overlap 
integral of donor and acceptor. The typical Förster distance is ranges from 1 to 
10 nm, and FRET is useful to study the biological macromolecules, as this dis-
tance is comparable to the diameters of many proteins and thickness of biologi-
cal membranes [40].  
In FRET-based sensors, energy transfer represents a dynamic type of 
quenching of the donor fluorescence and simultaneous increase of the acceptor 
fluorescence. Therefore, FRET efficiency can be detected in two modes [41]. In 
steady-state or stationary mode, a decrease of the donor’s FI, an increase of the 
acceptor FI and by change of the ratio of donor and acceptor FIs in dual channel 
mode measurements (at two wavelengths) are used to measure the FRET 
efficiency. In TR mode, decrease of the donor luminescence lifetime is meas-
ured. FRET efficiency measurement using luminescence lifetime change is the 
most accurate and reliable method, since the luminescence lifetime is independ-
ent of concentration of fluorophores, photo bleaching, changes in the intensity 
of the excitation light, and light scattering. 
FRET efficiency is defined as proportion of the donor molecules that have 
transferred excitation state energy to the acceptor molecules, which increases 
16 
with decrease in the intermolecular distance between the luminophores [42]. In 
experimental setup, the FRET efficiency can be calculated by measuring the 
change in the luminescence lifetime and intensity of the donor, using the fol-
lowing equations, 
 
 = 1 −	  (Equation 3) 
 
where, IDA is luminescence intensity of donor in the presence of the acceptor 
that leads to FRET and ID is luminescence intensity of donor in the absence of 
the acceptor.  
 
 = 1 −	  (Equation 4) 
 
where, τD is luminescence lifetime of donor and τDA is luminescence lifetime of 
donor and acceptor complex. 
Since FRET efficiency is dependent on the distance between two fluoro-
phores, it is a very promising spectroscopic tool to study interaction of biologi-
cal molecules. For example, protein-protein interaction, protein-ligand interac-
tion and conformational change of the proteins can be studied using the princi-
ple of FRET [43]. Especially after the availability of genetically encoded fluoro-
phores such as fluorescent protein (FP), various FRET-based sensors compris-
ing of FPs pairs were constructed. FRET-based sensors are very widely used in 
various fields, for molecular biology applications [44, 45], high-throughput 
screening assays [46], cancer imaging [47] and as an indicator of intracellular 
signaling molecules [48], etc. to name few. FRET pairs may be established 
utilizing non-fluorophore acceptors (quenchers), such as BHQ [49], and 
quenching of the donor fluorescence can be used to monitor the interaction 
between the donor and acceptor. Since FRET-based measurements are less 
interfered by non-target interactions, they are suitable for measurements in cell 
lysates and live cell based high-content screening assays [50].  
Although, FRET measurements are widely used in biochemical, biological, 
biomedical and medical studies, the measurements are often disturbed by the 
autofluorescence of biological samples. In that case, organic phosphorescent 
materials would be useful [51]. However non-organic, lanthanide based com-
plexes such as terbium and europium chelates, possessing long lifetime lumi-
nescence (in milliseconds range) are widely used in FRET studies [52]. The 
application of lanthanide complexes as partners in a FRET-pair and a TR 
measurement mode allows the elimination of short-lived background signals 
associated with the autofluorescence of biomolecules and scattered light with a 
time delay [41]. In addition, measurements with time delay detect only sensi-
tized fluorescence of the acceptor, and solve the problem of simultaneous fluo-
rescence excitation of the donor and acceptor, thereby increasing the dynamic 
range of measurements and the accuracy of the FRET efficiency determination. 
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3. Combining chemical and genetic approaches 
Interdisciplinary approaches, combining synthetic chemistry and protein engi-
neering are needed to develop novel opportunities for biomedical research, drug 
development and disease diagnostics [6, 7]. Thus chemical genetics has 
emerged as an important approach to study the biological systems. Chemical 
genetics can be defined as the study of biological systems using small-mole-
cules [53]. Classical genetics uses mutagenesis to elucidate the relationship 
between genes and phenotypes, whereas chemical genetics additionally employs 
small-molecule compounds [54]. Small-molecule compounds that intervene the 
biological systems by perturbing enzyme function or protein-protein interaction 
are used as tools in chemical genetics. Various protein modification techniques 
have been described to develop protein – small-molecule interfaces [55, 56]. 
This includes labeling a protein with a fluorescent dye [57], fluorescent protein 
(FP) tagging [6] , tetra cysteine motif-based labeling [58], enzyme mediated 
peptide tags, SNAP-tag, CLIP-tag and HaloTag [59, 60], labeling using trime-
thoprim conjugates [61] and introduction of unnatural amino acids [62] etc. 
All the protein modification techniques have their own pros and cons. Per-
haps the simplest technique is the FP tagging. Though fluorescently labeled 
proteins are widely used in various applications, the chemical labeling of a tar-
get protein in in vitro is difficult. Using genetic engineering techniques, a FP or 
a FP-tagged protein can be expressed in cells very easily. Though small, genet-
ically encoded non-FP tag such as tetra cysteine motif-based FlAsH and ReAsh 
tags [63] are available, but the application of such tags is minimal in recent 
times, compared to the use of FPs, in spite of challenges such as huge size and 
the oligomeric nature of FPs. The major advantage of FPs is that they do not 
need any external chemicals to become fluorescent. The fluorescence of the FP 
is originated from interaction of amino acid residues in the FP, which leads to 
the formation of the chromophore responsible for fluorescence, once the FP is 
functionally folded. This in contradiction with genetically encoded tetra cyste-
ine-based tags which require additional chemicals to be supplied into the cell for 
the fusion protein to become fluorescent and to be followed by thorough wash-
ing steps to remove the non-labeled substances. 
Chemical genetic approaches have been applied to PKs for various reasons 
[64], including the establishment of the interaction between a PK and a sub-
strate, the development of target specific inhibitors, the assignment of specific 
function to a PK in a signaling pathway, etc. A simple and reliable fluor-
escence-based technique for studying the interaction between PKAc and ligands 
using modified PK was demonstrated already 20 years ago. A mutated PKAc 
(N326C) was chemically labeled with acrylodan dye and fluorescence-based 
techniques were applied for studying the binding of PKAc with nucleotides and 
inhibitors [65]. In a classical chemical genetics approach [64], a gate keeper 
amino acid which is important for the binding of a substrate or a specific 
inhibitor, is replaced by a bulky amino acid. The point-mutated ‘analogue – 
sensitive’ PK is specific only to a particular set of inhibitors. On the other hand, 
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substrates and inhibitors are designed in such a way that they recognize only the 
modified PK and not the wild-type PK [66].  
In this study, a combination of chemical and genetic approaches was used 
for construction of sensor systems for analysis of PKs. Small-molecule organic 
probes with unique optical properties were developed and used together with 
PKs that were fused with complementary fluorescent proteins.  
 
 
4. The chemical approach: Development of small-molecule  
ARC-based photoluminescent probes 
Small-molecules are defined as carbon-based compounds whose molecular 
weight is usually under 500 Da and always less than that of macromolecules 
such as DNA, RNA, and proteins [54]. Small peptides refer to peptides with 
less than 30 amino acids or a molecular weight of less than 3500 Da [67]. ARCs 
(that are conjugates of a heterocyclic fragment and peptide or peptide analogue) 
possess MW of less than 2000 Da. Therefore, in line with the classification that 




4.1. Inhibitors of PKs 
Inhibitors of PKs have great practical value. Inhibitors of PKs are now widely 
used as drugs in clinical practice, but PK inhibitors are also used as research 
tools to study the regulation of cellular protein phosphorylation balances.  
Considering the importance of the pathophysiological roles of PKs, various 
pharmaceutical companies are involved in the process of developing inhibitors 
against the PKs. Since the approval of imatinib (Glivec®) by Food and Drug 
Administration of United States of America (FDA) in 2002, the number of ap-
proved kinase inhibitors has increased to 33, with many other PK inhibitors still 
in preclinical development. More than 130 kinase inhibitors are reported to be 
in phase-2 and phase-3 clinical trials [3]. Among them Glivec® dramatically 
improved the prognosis of patients with Chronic myeloid leukemia which is 
caused by constitutively active Bcr-Abl tyrosine kinase [68]. As most of the 
approved kinase drugs are active against more than one specific PK, only a few 
of them have been used for the treatment of non-oncological indications.  
Inhibitors that bind to the active site of a PK can be classified as inhibitors 
that are binding to the ATP-site, substrate protein-site or bisubstrate inhibitors 
which simultaneously associates with both substrate sites of the PK. The ATP 
binding site is conserved among all the PKs. Not only more than 500 PKs, but 
almost 1500 other proteins are known to bind purine nucleotides. Therefore, 
developing inhibitors that selectively target the ATP-binding site of a PK is 
challenging [69, 70]. On the other hand, the intracellular concentration of ATP 
is 1–10 mM, hence the inhibition potency of an ATP-competitive inhibitor 
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should be relatively high in order to compete with such a high concentration of 
ATP [71]. An inhibitor that possesses similar Ki values against multiple kinases 
will inhibit more potently those kinases in cells that have a higher ATP Km 
value[71]. 
Since the ATP-site is conserved among the PKs, substrate protein binding-
site offers more selectivity for development of inhibitors of PKs. Small-mole-
cule inhibitors of PKs targeting this site have been derived from both natural 
sources as well as by synthetic methods [72]. Pseudo-substrate inhibitors that 
mimic the consensus sequence of substrate proteins of PKs are also available. 
For example, the heat-stable protein kinase inhibitor, PKI and PKAr are the 
physiological inhibitors of PKA [73]. 
Despite the difficulties, development of ATP-competitive inhibitors for vari-
ous PKs is still progressing. For example, SGI-1776 is a potent inhibitor of PKs 
of PIM family, has been shown to be active against acute myeloid leukemia [74] 
both in in vivo and in vitro studies. A potent and selective inhibitor for CK2, 
targeting its ATP-site, namely CX-4945 has been shown to be active towards 
many forms of cancer in mice xenografts [75]. But still, these inhibitors have 
been shown to affect some off-target PKs to certain level. Thus making an in-
hibitor selective towards a single target PK is very difficult. For example, in-
hibitors that are comprising halogenated benzimidazole moiety as the ATP-
binding ligand inhibit both PK CK2 and PIM kinases [76]. In that case making 




4.2. The bisubstrate inhibitors of protein kinases: ARC-probes 
Bisubstrate inhibitors simultaneously bind to both substrate binding sites of the 
PK, hence they are conjugates of two fragments that associates to ATP-binding 
site and substrate protein binding-site of the PK. The bisubstrate character of an 
inhibitor towards a PK can be proved with the following methods [77]:  
1. X-ray analysis of PK/inhibitor co-crystals 
2. Kinetic analysis of the competitiveness of inhibitor against both 
substrates 
3. Displacement of the inhibitor from its complex with a PK by either ATP- 
or protein substrate-competitive inhibitors 
 
On the basis of ARC-compounds bisubstrate inhibitors of PKs have been devel-
oped in our research group [77]. ARCs are comprised of a heterocyclic frag-
ment (targeted to the ATP pocket of the PK) and a peptide or peptide analogue 
(targeted to the substrate protein-binding site of the PK), connected by a flexible 
linker. The acronym ARC is derived from the combination of words Adenosine 
analogue (A) and arginine (R)-rich peptide conjugate (C), representing the 
structural features of the first generation of ARC-based bisubstrate inhibitors 
[78]. Later on, various aromatic fragments and peptide analogues have been 
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introduced into the compounds, the acronym ARC has been retained for the 
historical perspective.  
The crystallographic studies enabled the optimization of the design of ARC 
compounds [79, 80]. This resulted in ARC compounds with improved selectiv-
ity and affinity towards a variety of PKs. The ARC inhibitors targeting baso-
philic PKs, such as PKAc, PIM, ROCK, PKB, etc., usually comprise D-arginine 
residues in the peptidic part, to achieve selectivity and resist proteolytic cleav-
age in the intracellular milieu [78, 81, 82]. Nevertheless, the peptidic part can be 
modified according to the origin of the target PK with other amino acids, based 
on the substrate consensus sequence of the PK.  
The ARC-compounds targeting the acidophilic PK CK2α comprise of an 
ATP-targeting heterocyclic moiety and an oligo-aspartate, the latter mimics the 
acidic substrate phosphorylated by the CK2α. Both D- and L-isomers of oligo-
aspartates have been utilized for developing ARCs targeting CK2α [83], as well 
as non-chiral peptoid analogue has been used in the peptide part [84]. Bisub-
strate inhibitors of CK2α incorporating oligo-glutamates were recently reported 
by another research group [85]. The ARC-compounds targeting mitotic PK 
Haspin, which phosphorylates histone H3 at Thr3, a peptide mimicking the N-
terminus of histone H3 was used was used as fragment of ARC [86]. Thus the 
ARC compounds have been widely modified at both the ATP-targeting and 
peptide mimetic parts. The simultaneous targeting of the ATP-binding site and 
substrate binding site of the PK by ARC compounds resulted in bisubstrate 
inhibitors possessing high affinity (Kd values in picomolar to nanomolar range) 
as well high selectivity.  
In addition to being potent inhibitor of PKs, the ARC-compounds that are 
labeled with luminophores are successfully applied as small-molecule probes in 
the High-throughput screening (HTS) of PK inhibitors using luminescence-
based detection methods [87].  
 
 
4.2.1. ARC-Photo probes 
ARC-Photo probes are ARC-compounds which incorporated a photolumines-
cent label such as a fluorescent dye (e.g., TAMRA, PromoFluor-647) or a lan-
thanide chelates (e.g., Lumi4Tb). ARC-Photo probes are used in luminescence-
based binding/displacement assays. Luminescence-based detection methods are 
safe, environment friendly and convenient, compared to the traditional radio-
ligand techniques. Inhibition assays using a fluorescently labeled substrates 
(e.g., TAMRA-labeled kemptide) were also developed which used thin layer 
chromatography for separation of the phosphorylated and non-phosphorylated 
fluorescent substrates [88]. 
FA-based assays for the characterization of affinity of PK inhibitors have 
been developed using fluorescently labeled ARC-photo probes (ARC-Fluo 
probes). Here, the association of the PK and ARC-Fluo probes is measured by 
means of change in fluorescence anisotropy/polarization (FA) and/or fluores-
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cence intensity (FI), hence it is a binding assay. The ARC-Fluo probe is used in 
FA-based displacement assay for the determination of dissociation constants 
(Kd) of inhibitors. FA-based binding/displacement assays using ARC-photo 
probes for inhibitors of basophilic kinases such as PKAc, ROCK [89], PKGα 
[90] and PIM [91] as well as acidophilic kinases CK2α [83] have been reported. 
Sometimes, the emission intensity of a PK-bound ARC-Photo probe is different 
compared to its free form. The ratio between the emission intensity of bound 
form and non-bound form of an ARC-Fluo probe is represented as the Q value 
and it is dependent on the structure of the ARC-probe, the conjugated fluores-
cent dye, and the PK used in the assay. ARC-Fluo probes, possessing higher Q 
values (Q > 2) were shown to be useful for the determination of dissociation 
constants of inhibitors towards cGMP-dependent protein kinase (PKGIα) in FI-
based measurements [90] using both a fluorescence plate reader and a 
spectrofluorometer. 
For FA-based assays, choice of the fluorescent dye is critical, as the affinity 
of the probe can be altered by the nature of the fluorescent dye. In FA-based 
assay, the range of resolvable affinities of compounds under evaluation is lim-
ited by the affinity of the fluorescent ligand [92]. The non-specific binding of 
fluorescent dye to the plastic or glass surface of the microtiter plate is a usual 
problem encountered in FA-based assay. For the same reasons, FA-based de-
tection methods are restricted to biochemical assay and not widely used in cell 
lysates and live cell-based assays, although few exceptions point to wider ap-
plicability of FA-based assays [93-95].  
ARC-Photo probes possessing fluorescent label (e.g., Alexa Fluor 647 etc.) 
or luminescent label (e.g., Lumi4Tb cryptate, europium cryptate etc.) are used 
in steady-state or TR FRET-based assays in combination with a genetically 
tagged PK (e.g., His6 tag) and an antibody (e.g., an anti-His6 antibody). Such 
multiplexed assays with various possible detection modes (FA, steady-state and 
TR FRET) are used for the characterization of protein-protein interaction be-




4.2.2. ARC-Lum probes 
ARC-Lum probes are organic, non-metal photoluminescent probes possessing 
protein-induced long-lifetime luminescence property [96]. ARC-Lum probes are 
ARC-type inhibitors of PK that produces micro-second scale photolumines-
cence upon binding to the PK in response to a near-UV radiation (300–370 nm). 
The fixation of the sulfur or selenium-containing heterocyclic ring of the ARC-
Lum probe to the ATP pocket of PK, results in protein-induced long-lifetime 
luminescence signal when the complex is excited with the flash of UV 
radiation, whereas the free probe produces very weak or no such signal. Sulfur 
and selenium are heavy atoms that support intersystem crossing of electrons in 
the excited state leading to the triplet activated state that may emit light as 
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phosphorescence. In contrast to the free (unbound) state of the probe, the hy-
drophobic and shielded environment in the ATP-binding pocket of the PK pro-
tects the exited triplet state from quenching by oxygen and restricts molecular 
movements, leading to increased phosphorescence and PK-binding responsive-





Figure 2. Mechanism of FRET in ARC-Lum probes illustrated by a Jablonski diagram 
adopted from [37, 39]. The donor luminophore of the ARC-Lum probe (sulfur or sele-
nium-comprising aromatic fragment), absorbs light at 330–370 nm and goes to the 
singlet excited state 1D* from the ground state 1D and emits part of its energy as fluores-
cence. Then the molecule undergoes intersystem crossing (ISC) to the triplet excited 
state 3D* and emits energy as phosphorescence or transfers energy to the singlet excited 
state of the acceptor fluorophore 1A* by FRET. Then the time-delayed emission from 
1A* state of donor fluorophore occurs.  
 
 
Two types of ARC-Lum probes were disclosed. If an ARC-Lum probes lacks a 
fluorescent dye, it is designated as an ARC-Lum(–) probe. ARC-Lum(–) 
probes, when associate with PKs possess a weak phosphorescence signal with 
microsecond-long decay time in the wavelength range from 450 to 650 nm. If 
an ARC-Lum probe additionally incorporates a fluorescent dye that is cova-
lently attached to the peptide moiety of its preceding ARC-Lum(–) counterpart, 
the probes is designated as an ARC-Lum(Fluo) probe. The conjugation of 
fluorescent dye to ARC-Lum(–) probe, if the absorption spectrum partly over-
laps with the phosphorescence emission spectrum of the complex PK/ARC-
Lum(–), leads to immense sensitization (up to a 1000-fold) of the luminescence 
signal. This effect is the result of intramolecular FRET (Figure 2) from the ex-
cited triplet state 3D* of sulfur- or selenium-comprising heteroaromatic system 
(phosphorescence donor, D) to the conjugated fluorescent dye (acceptor fluoro-
phore, A) leading to singlet excitation state of the acceptor 1A* and slow emis-
sion of light from acceptor fluorophore. Thus the emission spectrum of the tan-
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dem dye coincides with that of the fluorescent acceptor dye [97], but the decay 
of the signal is slow as it follows prohibited energy transfer from 3D* of donor 
to the singlet state of the acceptor. The acceptor fluorescent dye can also be 
conjugated to the interacting PK (e.g., PromoFluor-647-labeled PKAc) [96] 
provided that the acceptor fluorophores are located close enough to the donor 
phosphor of the ARC-Lum(–) probe to enable the intermolecular FRET to 
occur.  
Some features of ARC-Lum probes are 
 ARC-Lum probe comprises a heavy atom such as sulfur or selenium 
which supports the intersystem crossing serves as the phosphor or the 
phosphorescent donor 
 The near-UV excitation of the luminophore of ARC-Lum probe leads to a 
fluorescence emission in both unbound (free) form as well as in bound 
form with PK that ranges from 400 nm to 600 nm 
 An ARC-Lum probe emits phosphorescence at 450 to 700 nm only in its 
bound form with PK upon exciting with near-UV radiation and the un-
bound (free) form of the probe does not produce any phosphorescence  
 The time-delayed emission spectrum of ARC-Lum(Fluo) probes coin-
cides with the fluorescence emission spectrum of the conjugated dye 
 ARC-Lum(Fluo) probes possesses shorter luminescence lifetimes than 
their ARC-Lum(–) counterparts. The intramolecular FRET efficiency de-
pends on choice of the dye. The dye with high molar absorption coeffi-
cient and good spectral overlap leads to efficient FRET 
 The time-gated luminescence (TGL) signal intensity of PK/ARC-Lum 
probe complex is irrespective of the affinity of the probe to PK 
 As ARC-Lum(Fluo) probes are conjugated with a fluorescent dye, techni-
cally they are ARC-Fluo probes which can be also used in FA-based 
assays  
 
Since the discovery the ARC-Lum probes, their suitability for characterization 
of inhibitors of PK in biochemical assays [97] as well as cell lysate and live 
cell-based assays [96], analysis of biomarkers in blood plasma samples [98], 
mapping and monitoring PK activity in living cells by time-gated luminescence 
microscopy [99] has been demonstrated. 
 
 
5. The genetic approach: Labeling protein  
kinases with a fluorescent protein tag 
Manipulations involving FPs are done at the genetic level using gene engineer-
ing techniques, in contrast to other types of fluorophores where fluorophores are 
labeled to the protein of interest (POI) by an in vitro chemical coupling step 
[39]. The gene that encodes FP is ligated to either 5’-end (N-terminus of POI) 
or 3’-end (C-terminus of POI) of the gene that encodes POI without any inter-
24 
vening stop codons in an expression plasmid. Then the recombinant plasmid is 
introduced to the expression host by transformation (in case of a bacterial ex-
pression system) or transfection (in case of a mammalian expression system). 
The resulting translated gene product is a chimera of fusion protein that is co-
valently linking the POI and FP. As techniques are available for purifying FP-
tagged proteins [100, 101], the fusion proteins can be studied not only in com-
plex systems like cells and cell lysates, but also in homogeneous biochemical 
systems.  
Though monomeric FPs are preferred for fusions with POIs, the resulting 
oligomeric nature of the obtained fusion proteins is rather unpredictable and 
depends on the POI itself and the level of expression of the fusion protein. The 
tagging of the POI with a FP that is considered to be ‘silent’, may still lead to 
disruption of the normal function and localization of the POI. The positioning of 
the FP tag is another important aspect in producing the fusion protein chimera 
as the positioning of the FP tag is known to affect the localization of the target 
protein [102].  
 
 
5.1. Fluorescent proteins  
Fluorescent proteins (FPs) are class of homologues proteins having the ability to 
form a visible wavelength fluorophore from their own amino acid residues [39]. 
The discovery of green fluorescent protein (GFP) form the jelly fish Aequorea 
victoria, gained much attention by the scientific community after it has been 
shown that GFP can be expressed in Escherichia coli and Caenorhabditis ele-
gans with its intact fluorescence properties [103]. The ancestor of many widely 
used FPs is originated from the jelly fish Aequorea victoria [104]. Interestingly, 
red shifted FPs such as DsRed were derived from non-bioluminescent reef cor-
als of Anthozoa class [105]. Since then a quest for FPs from different natural 
sources has been explored. This resulted in a panel of FPs which covers almost 
the visible light region of electromagnetic spectrum from near ultra-violet (UV) 
to far infra-red (IR). The advancement in molecular biology techniques, such as 
error prone polymerase chain reaction (PCR) and site directed mutagenesis, 
enable the modification of the genes of native FPs, which in turn resulted in FPs 
with different spectral properties. For example, modifications in the native 
avGFP gene, resulted in variants of FPs such as cyan, enhanced green and 
yellow FPs [106]. Together avGFP and Anthozoan FPs such as DsRed served as 
the progenitors of numerous engineered variants of FPs that are have been used 
in various applications. The pioneering works of Osamu Shimomura, Martin 
Chalfie and Roger Y. Tsien, for the discovery and development of the green 
fluorescent protein, GFP, were marked by the 2008 Nobel prize award in 
chemistry [107]. FPs expressed with the POI by genetic engineering techniques 
enabled the scientific community to visualize the synthesis, localization and 
function of a protein in cells in real time using fluorescence microscopy. 
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The FPs (derived from avGFP and DsRed like FPs) are usually proteins of 
220 to 240 amino acids with a molecular weight of approximately 27 kDa 
[108]. The FPs are folded as an 11-standraded antiparallel β-sheet structure that 
is often referred as a β-barrel. The chromophore in avGFP is formed by a 
tripeptide S65-Y66-G67 [109] which is a part of a helix, located in the geomet-
ric center of the β-barrel structure of GFP. The tripeptide undergoes a cycliza-
tion – oxidation – dehydration reaction to form the chromophore, p-hydroxy-
benzylideneimidazolidinone. The enhanced GFP (EGFP) contains two 
mutations, S65T [110] and F64L [111], the former was to improve the spectral 
characteristic of the chromophore and the latter was to improve the folding at 
warmer temperature [106]. EGFP possesses excitation/emission maxima at 489 
nm/509 nm with an ε value of 55,000 M-1cm-1 and a QY of 0.6 [112]. In case of 
DsRed, the chromophore is formed by a similar tripeptide Q65-Y66-G67 [113]. 
The chromophore formation of DsRed and FPs derived from it, undergoes an 
additional oxidation that forms an acylimine (C=N–C=O). This reaction is fol-
lowed by an isomerization step that extended the π-conjugated electron system 
of the chromophore which is responsible for red-shifted absorbance and emis-
sion [113–115]. 
In live cell imaging, as a golden rule, red shifted FPs are better for biological 
studies [116]. Many of the RFPs are derived from DsRed, which is an obligate 
tetramer [117]. In fact, all FPs exhibit some degree of oligomerizations from 
weak head-to-tail dimerization (avGFP) to tetramerization (Anthazoan FPs). 
avGFP and FPs derived from it, are less prone to dimerization, hence the over-
expression of these proteins in bacterial or mammalian expression systems do 
not cause any aggregation or misfolding (avGFP is generally monomeric, but 
tends to form dimer with a Kd value of 110 µM [118]). But still RFPs with 
different oligomeric nature were derived from DsRed, thanks to protein engi-
neering techniques [119], such as DsRed express [120], DsRed-monomer [115, 
121], E2-crimson [122], mRFP1 [123]. The mFruit series [124] that includes 
numerous variants such as mOrange, tdTomato, mCherry and mPlum were also 
derived from DsRed. Today, color diversity of monomeric FPs covers almost 
the whole visible spectrum [112], from violet (e.g., Sirius [125]) to far-red (e.g., 
mKate [126]). The wider choice of monomeric FPs with various spectral 
properties, enabled to perform multi-parameter imaging of biological processes 
in living systems. However despite the availability of palette of red shifted FPs, 
none of them have achieved same level of widespread application compared to 
EGFP [127].  
 
 
5.2. The red fluorescent protein, TagRFP 
TagRFP [128] was chosen as the fluorophore for genetically tagging the PKs in 
the present study. TagRFP is a bright, pH stable, fast maturing, orange FP with 
desirable photophysical properties, generated from the wild-type RFP from sea 
anemone Entacmaea quadricolor. TagRFP is a 26.7 kDa (237 amino acids) 
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monomeric protein, however, partial dimerization of the protein at higher mi-
cromolar concentrations has been shown recently [129]. TagRFP has the pKa 
value of 3.8. TagRFP possess the QY of 0.48, ε value of 100,000 M-1cm-1 and a 
fluorescence lifetime of 2.3 ns with excitation/emission maxima at 555 nm/584 
nm. Some photophysical properties of TagRFP is very similar to the widely 
used chemical dye 5-carboxytetramethylrhodamine (TAMRA), hence the de-
tection of TagRFP is possible with filter sets of many fluorescence devices. 
TagRFP is about three times brighter fluorophore than another widely used 
RFP, mCherry [124], which makes it the one of the brightest commercially 
available monomeric RFPs.  
The chromophore formation of TagRFP is very similar to that of DsRed. The 
fluorophore of TagRFP originates from the tripeptide M67-Y68-G69 that forms 
5-[(4-hydroxyphenyl)-methylene]-imidazolone chromophore [130]. The DsRed-
like chromophore in TagRFP is converted into the GFP-like chromophore under 
acidic or alkaline conditions. This property has been observed for DsRed [113] 
itself and in purple-blue chromoprotein from the anemone coral Goniopora 
tenuidens [131].  
Nevertheless, TagRFP has been widely used in many FRET-based sensors 
[132]. For example, the genetically encoded TagGFP–TagRFP FRET pair is 
one of the most efficient green/red FRET pairs available [133]. The high extinc-
tion coefficient of TagRFP makes it a preferable FRET acceptor for green FPs 
and green dyes, such as fluorescein isothiocyanate (FITC) and HiLyte488. The 
emission spectrum of TagRFP overlaps with the absorption spectra of number 
of red dyes, such as Alexa Fluor 647 and Cy5, which makes TagRFP an effi-
cient donor fluorophore for various red dye-labeled acceptors. The higher 
quantum yield of TagRFP is beneficial for acceptor based ratiometric FRET 
studies. The FRET between TagRFP fusions and Lumi4Tb-labeled partners in a 
TR measurement of FRET also shown previously [41, 134]. Thus TagRFP has a 
great potential as a fluorophore for both steady-state and TR FRET applications. 
 
 
5.3. Tagging of protein kinases with fluorescent proteins 
The tagging of PKA with FPs was started along with the development of FPs 
themselves [106]. The applicability of FRET detection for PKA activity meas-
urement was demonstrated in two conceptual papers. Firstly, a sensor was 
designed for PKA in which the PKAc and PKAr subunits were each labeled 
with a different fluorescent dye, fluorescein and rhodamine, respectively capa-
ble for FRET in the holoenzyme complex [48]. Secondly, a cAMP sensor was 
engineered by fusing a blue-emitting FP to the PKAr subunit and a green-
emitting FP to the PKAc subunit [135]. Thus, when the concentration of cAMP 
is low, majority of the two fluorophores are in close proximity and generate 
FRET, whereas increasing concentration of cAMP leads to progressive reduc-
tion of FRET as the two fluorophores diffuse farther apart. An improved cAMP 
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sensor of cyan fluorescent protein (CYP)-fused PKAr and yellow fluorescent 
protein (YFP)-fused PKAc pair was developed later [136].  
The generation of FP-tagged PKAc turned out to be very challenging as it 
required a lot of optimization of the structures of fused proteins [106]. A lot of 
research was carried out for optimization of expression procedures for GFP-
fused PKAc [106, 137, 138]. The construction of an intermolecular FRET-based 
fluorescent sensor, incorporating an interacting protein tagged with a FP, is 
normally a trial and error process, given because of the difficulty of reliable 
prediction how the chromophores fused to the sensor will orient themselves in 
space relative to each other [139]. 
PKs that are tagged with N- or C-terminal FP exhibit different behavior, 
concerning their localization and activity. The N- and C-terminally GFP-fused 
PKAc reveals different localization [140], where the former is evenly distrib-
uted in cytoplasm and is excluded from the nuclear compartment, and the latter 
is found in the form of fluorescent aggregates in cytoplasm. Nuclear pores are 
thought to allow passage of globular proteins with molecular weight of less than 
45–60 kDa [141], thus the localization of fusion proteins is mainly dependent 
on the size, function, and oligomeric nature of POI. The study of interaction 
between the GFP-tagged PKAc and Renilla reniformis luciferase-tagged PKAr 
that was analyzed by intermolecular bioluminescence energy transfer (BRET) 
between the luminophores, shows that the BRET efficiency depends on the 
positioning of the FP tag on PKAc [138]. The positioning of not only FP tag, 
but also other purification tags that are attached to PKs, have huge impact on 
the FRET efficiency between the tagged PK and interacting partner. Tyrosine 
kinases possessing N- and C-terminal positioning of biotin tag, His6 tag and 
GST tag have been shown to have different FRET efficiency in biochemical 
assays involving the FRET between europium cryptate-labeled anti-tag anti-
bodies and Alexa Fluor 647-labeled inhibitors [142]. These facts point to the 
importance of positioning of FP tag to PK not only for its effect on FRET effi-
ciency but also for activity of the PK. 
 
 
6. Combining small-molecule ARC-probes and  
fluorescent protein-tagged protein kinases 
In this study genetically modified PKs and ARC-probes are combined together 
to develop FRET-based sensors for various applications. One hand, small-mole-
cule ARC-probes incorporating various aromatic systems and possessing di-
verse luminescent properties are developed. On the other hand, PKs with ge-
netically fused FP tags are developed. The combination of these two entities led 
to the construction of FRET sensors and their application for screening of PK 
inhibitors is described.  
FRET between the fluorophores of FP-fused PKs and ARC-Photo probes has 
been previously demonstrated for biochemical assays and live cell experiments. 
The application of ARC-Photo probes for monitoring the activity of PKA using 
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the FRET between C-terminally YFP-fused PKAc and TAMRA-labeled ARC-
Photo probe (ARC-TAMRA) has been described using C9H6 [135, 139] cell 
line that is stably expressing PKAr-CFP and PKAc-YFP [143]. The FRET be-
tween the fluorophores of PKAc-YFP and cell permeable ARC-TAMRA probe 
was detected in live cells and the effect of cAMP and H89 on FRET was ana-
lyzed using a fluorescence microscope. Thereafter an in vitro assay was devel-
oped in HTS format which employed a fluorescent plate reader. However, in 
this study, cell-to-cell signal heterogeneity resulted in lower signal-to-noise 
ratio in the plate reader assay compared to the detection of FRET in individual 
cells. In another study, the FRET between PKGα fused with a pH-insensitive 
YFP, citrine [144] and ARC-TAMRA was demonstrated [90]. The purified 
fusion protein, cygnet 2.1 [145] which consists of a mutant PKGα with N-termi-
nal ECFP and C-terminal citrine, was used as the FP-fused PK. The FRET be-
tween citrine of cygnet 2.1 and an ARC-TAMRA probe was established and the 
system was used to characterize the affinity of inhibitors using a spectrofluo-
rometer. However the difficulties in purifying FP-tagged PKs and the instability 
of purified fusion proteins restrict the application of such a FRET sensor for 





Figure 3. Spectral overlap between the excitation and emission spectra of TagRFP with 
fluorescence dyes (A) and Lumi4Tb terbium cryptate (B).  
 
 
In order to achieve the selectivity towards the target PK in a complex biological 
solution like cell lysate, the PK was tagged with a FP, TagRFP. Then FRET 
between ARC-Photo probes and TagRFP-fused PKs was established. Shifting 
the emission wavelengths of FRET pairs towards the red region of the spectrum 
reduces of the background cellular autofluorescence and generally increases the 
FRET efficiency due to increased R0 values [146] . Hence it was decided to 
combine TagRFP-fused PKs and ARC-Photo probes that are labeled with red 
dyes for construction of a steady-state FRET sensor. For TR version of FRET, 
ARC-Photo labeled with terbium cryptate, Lumi4Tb and TagRFP-fused PKs 
were used.  
The emission spectrum of TagRFP overlaps with the absorption spectra of 
various red dyes such as PromoFluor-647 (PF647), Alexa Fluor647, Cy5, and 
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Atto647N (Figure 3A). Hence TagRFP fused to PK can be used as a donor 
fluorophore for ARC-Photo probes with these red dyes. Thus, the FRET assays 
involving steady-state FI measurement between the donor and acceptor fluoro-
phore were developed. On the other hand, the absorption spectrum of TagRFP 
overlaps with the emission peaks of Lumi4Tb (Figure 3B). Hence, the TR 
measurement of FRET is also possible with TagRFP. Also the absorption spec-
trum of TagRFP overlaps with the phosphorescence emission spectra of some 
ARC-Lum(–) probes. Hence the triplet–singlet FRET between the luminophores 
of sulfur/selenium-comprising aromatic fragment of ARC-Lum(–) probe and 
TagRFP-fused PKs is possible provided that the direct phosphorescence 
emission of PK/ARC-Lum(–) complex can be discriminated from the long-lived 
emission of TagRFP. Thus TagRFP plays a multiple role in various FRET sen-
sors based on their application in combination with ARC-probes.  
The complementation between the genetically fused PKs and small-molecule 
ARC-probes helped to improve our understanding of PKs. This supported the 
development of structurally diverse ARC-probes and ARC-inhibitors which can 
be used for biochemical and biomedical research. 
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AIMS OF THE STUDY 
The general aim of the study was the development of photoluminescence-based 
assay systems for PK analysis by combining genetic engineering techniques for 
expression of PKs fused with FPs in mammalian cells and chemical methods for 
synthesis of photoluminescent ARC-probes for the characterization of PKs and 
their inhibitors in cell lysates. The specific aims of the study are: 
 Cloning of recombinant plasmids that encode PKs, PKAc, PIM and 
CK2α together with a genetically encoded FP tag, TagRFP, and optimi-
zation of their expression in mammalian cells 
 Development of small-molecule ARC-Lum probes for PKs PKAc, PIM 
and CK2α and establishing their optical and biochemical properties 
 Development of photoluminescence-based assays using TagRFP-fused 
PKs and ARC-probes in cell lysates 
 Establishing multiple FRET mechanisms between luminophores of ARC-
Lum probes and the TagRFP-fused PKs 
 Analyzing the possibilities of ARC-Lum probes for determination of PIM 





1. Cloning of protein kinase genes 
The genes that encode human PKAc, CK2α, PIM1 and PIM2 were obtained 
with custom designed restriction sites from Genewinz Inc. in pUCKan57 vector 
as shown in Table 1. These plasmids were used as the donor plasmid for the 
recombinant plasmids. The pTagRFP vectors contain Kozak [147] consensus 
translation initiation site (gccacc) at 5’ of the TagRFP gene, and the same 
Kozak consensus sequence was used at 5’ of the GOI. 
 
 
Table 1. Custom-designed donor plasmids 
Plasmid Design Encoding PK 
pUCKan-PKAc NheI-Kozak-PKAc-SacI PKAc (40 kDa) 
pUCKan-CK2α NheI-SalI-Kozak-CK2α-HindIII-Stop-
BamHI 
CK2α (45 kDa) 
pUCKan-PIM1 NheI-Kozak-PIM1-HindIII PIM1 (35.7 kDa isoform) 
pUCKan-PIM2 NheI-BglII-Kozak-PIM2-HindIII-Stop-
PstI 
PIM2 (34.2 kDa isoform) 
 
 
Using a pair of restriction enzymes, each one from 5’ and 3’ primes, the GOI 
was excised from the donor plasmid and cloned into various vector plasmids. 
Thus the custom designed gene can be used a source plasmids for various re-
combinant plasmids. In case of C-terminal fusion of TagRFP, the gene was 
excised without a stop codon, whereas for N-terminal fusion of TagRFP the 
GOI was excised with a stop codon. Recombinant plasmids produced in this 



























pTagRFP-N NheI SacI phCa-TagRFP C-terminally 
TagRFP-fused PKAc 
via 17 amino acid 
linker (68.6 kDa) 
phCa-
TagRFP 
pDsRed1-N1 NheI HindIII phCa-DsRed1 C-terminally 
DsRed1-fused PKAc 
via 21 amino acid 
linker (68.9 kDa) 
pUCKan-
PIM1 
pTagRFP-N NheI HindIII pPIM1-TagRFP C-terminally 
TagRFP-fused PIM1 
via 17 amino acid 
linker (64.5 kDa) 
pUCKan-
PIM2 
pTagRFP-N NheI HindIII pPIM2-TagRFP C-terminally 
TagRFP-fused PIM2 
via 17 amino acid 
linker (63 kDa) 
pUCKan-
PIM2 
pTagRFP-C BglII PstI pTagRFP-PIM2 N-terminally 
TagRFP-fused PIM2 
via 7 amino acid 
linker (61.8 kDa) 
pUCKan-
PIM2 
pTagRFP-C NheI PstI pCMV-PIM2 Full-length native 
PIM2 (34.4 kDa) 
pUCKan-
CK2α 




via 19 amino acid 
linker (74 kDa) 
pUCKan-
CK2α 




via 17 amino acid 
linker (73.8 kDa) 
pUCKan-
CK2α 
pcDNA3.1(+) NheI BamHI pcDNA-CK2α Full-length native 








Table 3. Recombinant plasmids produced for expressing the PKs with a His6 tag or as a 











pTagRFP-N pET28a SacI NotI pET-
HisTagRFP 
TagRFP tagged with N 




pET28a NheI HindIII pET-
HisPKAcHis 
PKAc tagged with N and 




pET28a NheI NotI pET-
HisPKAcRFP 
PKAc tagged with N 
terminal His6 tag and C 




pET28a NheI HindIII pET-
HisPIM1His 
PIM1 tagged with N and 




pET28a NheI NotI pET-
HisPIM1RFP 
PIM1 tagged with N 
terminal His6 tag and C 




pET28a NheI HindIII pET-
HisPIM2His 
PIM2 tagged with N and 




pET28a NheI NotI pET-
HisPIM2RFP 
PIM2 tagged with N 
terminal His6 tag and C 




pET28a NheI SalI pET-HisPIM2 PIM2 tagged with N 




pET28a NheI HindIII pET-
HisCK2αHis 
CK2α tagged with N and 




pET28a SalI BamHI pET-HisCK2α CK2α tagged with N 








CK2α tagged with N 
terminal His6 tag and C 




Transfection is a method by which a foreign DNA, such as a plasmid DNA is 
introduced into mammalian cells. The cells that are transfected are called as 
trasnfectants [148]. The introduction of a plasmid DNA into bacterial cells is 
called transformation. Transfection is used to express a foreign protein or over-
express a protein of interest (POI) in the mammalian cells. Transfection can be 
classified stable or transient transfection. In case of stable transfection, the for-
eign DNA is integrated into the genome of host. An antibiotic is used to select 
cells that contain the foreign DNA and they are established as stable cell line 
that expresses the POI. In case of transient expression, the foreign DNA is not 
integrated into the genomic DNA of host, but the genes are expressed for a 
specific period of time (24–96 h).  
For transient expression of a plasmid DNA, various transfection reagents and 
techniques are available. Transfection reagents includes lipid-based reagents 
(e.g., Lipofectamine™), cationic polymers (e.g., TurboFect™, diethylami-
noethyl-Dextran), calcium phosphate, etc. Electroporation, microinjection and 
laserfection are mechanical means of delivering the foreign DNA into cells. 
Transfection methods using viral vectors are also in practice. However, it is not 
guaranteed that a particular reagent or method will work for all cell lines. 
Various factors can affect the transfection including, the passage number of 
the cells, confluency of the cells during transfection, presence of serum in the 
growth medium and the quality of the plasmid DNA. The successful expression 
of PKs and fusions of PKs in mammalian cells may need a lot of optimization. 
In addition to common problems with the transfection reagents, other criteria 
may influence the PK expression, for example overexpression of the PK may be 
toxic to cells. The efficiency of transfection and expression of a particular PK 
greatly vary among various cell lines (e.g., cancerous or non-cancerous). 
 
 
3. Determination of dissociation constant of inhibitors 
The binding efficiency between an enzyme and a ligand is characterized by the 
value of the dissociation constant KD. Lower KD value represents higher affinity 
between a ligand and enzyme. The KD value is expressed as follows,  
 
 = [ ][ ][ ]  (Equation 5) 
 
[E], [L], [EL] are equilibrium concertation of an enzyme, a ligand and their 
complex, respectively.  
If the equilibrium dissociation constant between a PK and an ARC-Photo 
probe is determined from a direct binding assay with FA or TGL read-out [89, 
97], the constant it is denoted as KD. 
The affinity of a non-labeled inhibitor is determined from FA or TGL-based 
displacement assay, using an ARC-Photo probe. In this case, the IC50 value 
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which represents the concertation of the inhibitor at which 50% of the ligand 
(ARC-Photo probe) is displaced from its complex with a PK is measured. Form 
the IC50 value, the equilibrium dissociation constant (Kd) of a non-labeled in-
hibitor is obtained using the following Cheng-Prusoff equation [149],  
 
 = [ ]  (Equation 6) 
 
Kd is the dissociation constant of the complex of PK and the inhibitor, KD is the 
dissociation constant of the complex of PK and the ARC-Photo probe and [L] is 
the concentration of the ARC-Photo probe used in the assay. 
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RESULTS AND DISCUSSION 
1. Production of protein kinases with genetically  
encoded tags (Paper II, IV and unpublished data) 
Gene engineering techniques were applied for producing genetically tagged 
PKs. This study is focused on PKs of the PIM family, PKAc, and CK2α. Re-
combinant plasmids that encode fusion proteins of PKs with TagRFP and His6 




1.1. Expression of TagRFP-fused PKs 
The genes of PKs were cloned into pTagRFP vectors to produce recombinant 
plasmids encoding fusion proteins of PKs with TagRFP in mammalian expres-
sion system. Plasmids were introduced into mammalian cells by transfection 
and the recombinant proteins were transiently expressed. The PKAc fusions 
were expressed in HeLa cells whereas fusion proteins of PIM kinases and CK2α 
were expressed in NIH/3T3 cells. 
The TagRFP-fused PKs were expressed in two forms, with N- and C-termi-
nal positioning of TagRFP. The FI of lysates of cells overexpressing TagRFP-
fused PKs was compared with FI of recombinant TagRFP or an ARC-TAMRA 
probe, ARC-669. In general the expression level of N-terminally TagRFP-fused 
PKs was higher than that of C-terminally TagRFP-fused PKs (e.g., PKAc and 
CK2α fusions). However in case of PIM2 fusions, both forms of the fusion 




Figure 4. Fixed cell imaging of PKAc-TagRFP (left) and TagRFP-PKAc (right) in 
HeLa cells using a confocal microscope. 63X oil objective. Pseudo colored images with 
DAPI channel (blue) and TagRFP channel (red). 
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Lysates of cells overexpressing TagRFP-fused PKs were subjected to Western 
blot analysis using an anti-TagRFP antibody (Paper II, Figure S2 and Paper IV, 
Figure S2). MWs of all fusion proteins found from Western blots were slightly 
smaller than their predicted molecular weights. Also, two bands were observed 
for the TagRFP-fused PKs at the predicted MW, with the MW difference of 
approximately 8 kDa. This has been reported to result from the cleavage of 
acylimine band in the DsRed-like chromophore structure of TagRFP (M67-
Y68-G69) during the heat denaturation [113, 131, 133]. Lysates were analyzed 
using anti-PK specific antibody to compare the level of endogenous expression 
of a PK in host cells (e.g., PKAc and CK2α) and the over expression of 
TagRFP-fused PK (Paper II, Figure S3 and Paper IV, Figure S3). HeLa and 
NIH/3T3 cells expressed native PKAc and CK2α at significantly high level. But 
there was almost no endogenous expression of PIM2 in NIH/3T3 cells. It is 
interesting to note that attempts to overexpress PIM2 fusions in HeLa and PC3 
cells failed, while it was successfully expressed in NIH/3T3 cells, a non-cancer-
ous cell line, which is lacking endogenous PIM2 expression [27]. 
PKs that are genetically tagged with N- and C-terminal FP, in present case 
TagRFP, should be treated as two different proteins. Both the expression level 
as well as the intracellular localization of FP-tagged PKs was dependent on the 
positioning of the FP in the fusion with the PK [140]. The localization of 
TagRFP-fused PKs was studied using fluorescence microscopy techniques 
(Figure 4 and Paper IV, Figure S1). TagRFP-fused PKs are distributed all over 
the cell and localized both in cytoplasm as well as in nucleus. In general, no 
difference in the localization of N- and C-terminally TagRFP-fused PKs were 
observed for PKAc, CK2α and PIM2 in the current study. 
 
 
1.2. Expression of fusion proteins of PKs in bacteria 
The genes of PKs were cloned into pET expression vector in order to produce 
PKs with His6 tag at N-terminus, C-terminus or at both termini of PKs in E.coli. 
Recombinant plasmids encoding PKs with N terminal His6 tag and C-terminal 
TagRFP fusion were also produced. This allowed the production and purifica-
tion of His6-tagged PKs in large quantities. The tagged proteins were further 
purified using nickel affinity columns.  
The recombinant purified His6 tagged PKs were used in biochemical assays 
together with ARC-Photo probes and antibodies. FA-based multiplexed assays 
utilizing ARC-Photo probes, anti-His6 antibody and His6 tagged PKs are under 
development in the research group. These assays could be converted to steady-
state or TR FRET format using ARC-Photo probes (with a fluorescent label or a 
photoluminescent label with long decay time, such as terbium and europium 
cryptate) and fluorescently labeled anti-His6 antibodies or terbium or europium 
cryptate-labeled anti-His antibodies. Thus the His6-tagged PKs are potential 
tools for the development of multiplexing assays. These assays are expected to 
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be also useful for the characterization of protein-protein interactions, e.g., be-
tween antibodies and a PKs. 
 
 
2. Development of ARC-Lum probes for protein  
kinases (Paper I, III, IV and unpublished data) 
Since the discovery of protein binding-induced long-lifetime luminescence 
property of sulfur- and selenium-comprising aromatic systems, various het-
eroaromatic rings have been utilized for the construction of ARC-Lum probes. 
The very first ARC-Lum probes were comprised of two different monocyclic 
aromatic rings connected by a rotatable single bond. These bicyclic compounds 
comprised of either a thiophene or selenophene ring as the phosphorescence 
donor [96]. For example, the ARC-Lum probe ARC-1063, comprised of an 
amino pyrimidine ring and a thiophene ring connected by a C–C bond (Figure 
5). The protein binding-induced long-lifetime photoluminescence is stronger in 
case of selenophene-comprising compounds compared to thiophene-comprising 
compounds. For example, ARC-1139 is a selenophene-comprising counterpart 
of thiophene-comprising probe ARC-1063. The TGL intensity of ARC-
1139/PK complex is about 5–20-fold higher than that of ARC-1063/PK com-
plex. Hence the selenium-comprising aromatic fragments are more promising 





Compound X Y 
ARC-668 S H 
ARC-669 S TAMRA 
ARC-1182 S PF647 
ARC-1063 S Alexa647 
ARC-1138 Se H 
ARC-1139 Se PF647 
Figure 5. Structure of ARC-Lum probes targeting basophilic kinases. 
 
 
The selenophene-containing ARC-Lum probe ARC-1139 gave the protein-in-
duced long-lifetime signal with many basophilic PKs, including PIM kinases. 
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Though, ARC-1139 is 250–800-fold more affine towards PKAc, than to PIM 
kinases, ARC-1139 was still successfully used for the characterization of PIM 
kinase inhibitors using a TGL-based displacement assays [91]. Hence the con-
struction of ARC-Lum probes possessing high selectivity and affinity towards 
PIM kinase was challenging.  
 
 
2.1. ARC-Lum probes comprising benzoselenadiazole moiety 
 
 
Compound X  Compound X 
ARC-3131 H  ARC-3138 H 
ARC-3132 PF647  ARC-3141 PF647 
Figure 6. Structures of benzoselenadiazole-comprising ARC-Lum probes. 
 
 
A new aromatic scaffold based on benzoselenadiazole fragment was introduced 
for ARC-Lum probes. Benzoselenadiazole is a fused tricyclic ring system, 
which is more rigid compared to the previous ARC-Lum probes, thus the posi-
tioning of this fragment to the PK is more predictable. Also the synthesis of 
ARC-Lum probes with benzoselenadiazole scaffold is relatively easier, hence 
various substitutions are possible.  
To develop PK-specific ARC-Lum probes that incorporate benzoselenadi-
azole fragment, bisubstrate inhibitor approach was applied. The benzoselenadi-
azole moiety was connected to an oligo-arginine or an oligo-aspartate peptide 
via a flexible linker (Figure 6). The oligo-arginine conjugated benzoselenadi-
azole (ARC-3131) was an ARC-Lum(–) probe targeting basophilic PKs, in-
cluding PKAc and PIM kinases, and an oligo-aspartate conjugated benzose-
lenadiazole compound ARC-3138 was an ARC-Lum(–) probe for an acidophilic 
PK CK2α.  
The phosphorescence emission maximum of these compounds is at 600–650 
nm, hence red fluorescent dye PF647 was chosen as the phosphorescence 
acceptor. The luminescence lifetime (τ) of ARC-3131 and ARC-3138 in com-
plex with PKAc and CK2α was 55 µs and 26 µs, respectively. ARC-3131 and 
ARC-3138 were labeled with PF647 to yield ARC-Lum(Fluo) probes ARC-
3132 and ARC-3141, respectively. The labeling of ARC-Lum(–) probes with 
the acceptor dye PF647 led to the amplification of TGL signal by 250-fold and 
400-fold for PKAc complex and CK2α complex, respectively (Paper I, Figure 
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S5). The luminescence lifetime of ARC-3132 and ARC-3141 in complex with 
PKAc and CK2α was 45 µs and 20 µs, respectively (Paper I, Figure S3 and S4). 
This corresponds to approximately 20% of intramolecular FRET efficiency. The 
KD values of ARC-3132 and ARC-3141 towards PKAc and CK2α were 46 nM 
and 25 nM, respectively (Paper I, Figure 1). The probe, ARC-3141 was the first 
ARC-Lum(Fluo) probe constructed for the acidophilic PK CK2α. The devel-
oped probe was used for the determination of CK2α concentration in cell 
lysates.  
However the probe ARC-3132 failed to produce long-lifetime luminescence 
signal with PIM kinases. On the other hand, the binding of ARC-3132 to PIM 
kinases resulted in increase in FA value (Paper I, Figure 1). The binding curve 
matched to KD values of 6 nM, 54 nM and 35 nM for PIM1, PIM2 and PIM3, 
respectively. The TGL signal of ARC-3132/PKAc complex was 300-fold 
stronger than that of ARC-3132/PIM2 complex. This result was quite unex-
pected as several previously reported ARC-Lum probes were capable of pro-
ducing luminescence with many basophilic kinases, including kinases of the 
PIM family. The reduced TGL signal of complexes of ARC-3132 with PIM 
kinases could be resulting from the unique structure of the hinge region of PIM 
kinases, all possessing an amino acid residue proline at the position 123 in the 
hinge region, where other PKs have a valine residue. Proline residue lacks the 
hydrogen bond donor properties for binding ligands [150].This interaction 
seems to be important for stabilization of the triplet electron state of the donor 
phosphor. CK2α that is possessing a more common Val116 residue in this posi-
tion is able to give the required hydrogen bond. Because of its unique hinge 
region [20], construction of specific probes for PIM kinases was challenging.  
 
 
2.2. ARC-Lum probes comprising benzoselenopyrimidine moiety 
Bisubstrate inhibitors comprising of benzothienopyrimidine and an oligo-argi-
nine peptide were developed for PIM kinases [91]. Conjugation of benzothieno-
pyrimidine and hexa-arginine via a flexible linker yielded ARC-3104 (Figure 7) 
possessing 4000–8000-fold higher affinity towards PIM kinases compared to 
PKAc. The compound was labeled with PF647 to yield the ARC-Lum(Fluo) 
probe ARC-3117 which was used in assays with PIM kinases using FA read-
out. This probe had subnanomolar affinity towards PIM kinases and high 
selectivity (500-fold) over PKAc. However the probe produced very weak or no 
luminescence signal with PIM kinases and therefore was not developed further 
as an ARC-Lum probe. 
We hypothesized that replacing sulfur atom in benzothienopyrimidine with 
heavier selenium atom could improve the phosphorescence properties of the 
donor phosphor (Paper III, Figure 1). Thus ARC-Lum probes containing ben-
zoselenopyrimidine moiety were developed. The sulfur atom of ARC-3104 was 
replaced with selenium, to yield ARC-3157 (Figure 7). As expected the ARC-
Lum(–) probe ARC-3157 produced 100-fold stronger long-lifetime lumines-
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cence signal if bound to PIM kinases as well as PKAc than its sulfur counter-
part. These probes possessed 500-fold higher affinity towards PIM kinases 
compared to PKAc.  
ARC-3157 produced 3–7-fold stronger TGL signal with PIM2 kinase com-
pared to other kinases of PIM family (Paper III, Figure 4). But this probe pos-
sessed a stronger TGL signal intensity with PKAc also. The luminescence life-
time of ARC-3157 in complex with PIM2 and PKAc was 84 ± 10 µs and  
132 ± 22 µs respectively. However, these probes had more than 100-fold 
selectivity for PIM kinases compared to PKAc. For example, ARC-3158 (ARC-
3157 conjugated with PF647 dye), possessed a KD value of 0.7 ± 0.3 nM and 
187 ± 58 nM towards PIM2 and PKAc, respectively. So at low PK con-
centration ARC-3158 generates a PIM-2-selective signal, but at higher (micro-
molar) concentration PKAc (and probably some other PKs of the AGC group) 





Compound  X Y Z 
ARC-3104 S H 6 
ARC-3117 S PF647 6 
ARC-3157 Se H 6 
ARC-3158 Se PF647 6 
ARC-3159 Se PF555 6 
ARC-3160 Se H 9 
ARC-3161 Se PF647 9 
ARC-1451 Se TAMRA 6 
ARC-1452 Se FITC 6 
ARC-1454 Se Atto647N 6 




2.2.1. Effect of dye on intramolecular FRET efficiency  
The phosphorescence emission of ARC-3157/PIM2 complex was ranging from 
450 to 600 nm and possessed a maximum at 500 nm (Figure 8). Thus fluores-
cent dyes possessing strong absorption in green region of visible spectrum, such 
as PromoFluor-555 (PF555) and TAMRA were found to be suitable acceptors 
for the phosphor of ARC-3157.  
The phosphorescence emission from the phosphor of ARC-3157 complex is 
amplified by the fluorescent acceptor dye that is incorporated into ARC-
Lum(Fluo) probes derived from ARC-3157 in complexes with PKs. The mag-
nitude of signal amplification depends on the spectral overlap between the ab-
sorption spectrum of the dye and phosphorescence emission spectrum of phos-
phor as well as other photophysical properties of the acceptor fluorophore, such 
as molar absorption coefficient and QY (Table 4).  
 
 
Figure 8. Overlap of the phosphorescence emission spectrum of ARC-3157/PIM2 com-
plex and absorption spectra of various fluorescent dyes and TagRFP. 
 
 
Table 4. Optical and biochemical characters of some ARC-Lum(Fluo) probes derived 
from ARC-3157. 
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ε value  
(M-1cm-1) 
QY 
ARC-3158 PF647 250,000 0.4 67 ± 10 20% 0.7 ± 0.3 1.5 
ARC-3159 PF555 150,000 0.135 51 ± 4 40% 1.8 ± 0.5 1.3 
ARC-1451 TAMRA  80,000 0.3 47 ± 5 45% 2 ± 1.5 1.8 
ARC-1452 FITC 75,000 0.7 45 ± 10 46% 5 ± 2 1.5 
ARC-1454 Atto467N 150,000 0.65 74 ± 5 12% 3 ± 1.5 1.6 
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The FITC-labeled compound ARC-1452 resulted in 46% of intramolecular 
FRET efficiency though the ε value of the dye is smaller. This efficient energy 
transfer resulted from the good overlap of the absorption spectrum of FITC with 
the phosphorescence emission spectrum of ARC-3157/PIM2 complex (Figure 
8). The energy transfer to PF647 (E = 20%) labeled compound ARC-3158 is 
higher compared to Atto647N (E = 12%) labeled compound ARC-1454. This 
indicates that energy from selenium-comprising heteroaromatic system (phos-
phorescence donor) is more efficiently transferred to the acceptor fluorophore 
PF647 than to Atto647N Although the absorption spectra of both fluorophores 
have similar overlap with the phosphorescence emission spectrum of ARC-
3157, the more efficient energy transfer may reflect the higher molar absorption 
coefficient of PF647 compared to that of Atto647N. 
 
 
2.2.2. Effect of dye on the binding of ARC-probe with PK 
The ARC-Lum(–) probe ARC-3157 has Kd value of 0.4 nM towards PIM2 ki-
nase. Various ARC-Lum(Fluo) probes were derived from ARC-3157 by label-
ing of the latter with different dyes. The attached dye altered the binding of the 
probe to PIM2 which resulted in different KD values. The TAMRA-labeled 
probe, ARC-1451 revealed high Q value that points to the nonspecific binding 
of the probe to surface of microplate. The binding of Atto647N-labeled com-
pound ARC-1454 with BSA was detected in an assay with FA read-out. Titra-
tion of the probe with BSA revealed the KD value of 1.7 µM (Paper IV, Figure 
S6). Atto647 dye possesses nonspecific binding to different proteins and sticks 
to glass and plastic surfaces because of its high lipophilicity and low polarity 
[151]. Therefore, Atto647N was not used for labeling of probes for cell lysate-
based assays. PF647-labeled probe ARC-3158 is well suitable for measure-
ments based on the FA read-out (Paper IV, Figure S11) also. Although both 
probes are usable in TGL-based measurements, PF647 is still a better dye for 
the construction of photoluminescence probes for measurements in biological 
solutions and cells as it shows less intense nonspecific interactions with lysate 
components and plastic and glass surfaces. 
 
 
2.3. Cellular delivery of ARCs comprising an  
oligo-aspartate peptide using a transfection reagent 
Peptides that are rich in cationic amino acids have been shown to be cell perme-
able and used widely as vehicles to deliver cell plasma membrane-impermeable 
compounds [152, 153] as well as nucleic acids [154] into cells. The ARC-
probes that are conjugated with oligo-arginines are effectively taken up cells 
and their application for studying PKs in live cells has been demonstrated [143]. 
Because of their effective cellular uptake, live cell in vitro assays employing 
oligo-arginine comprising ARC-probes have been developed [96].  
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However, peptides and peptide conjugates comprising several aspartate resi-
dues are poorly penetrating the cell plasma membrane due to their negative 
charge. Thus the development of in vitro assays for monitoring the activity of 
PK CK2 using oligo-aspartate comprising ARC-probes is challenging. In that 
case, masking of the negative charge of the oligo-aspartate moiety is necessary, 





Figure 9. An ARC-Photo probe incorporating an oligo-aspartate and TAMRA dye 
(ARC-1505) delivered into NIH/3T3 cells using TurboFect transfection reagent. Live 
cell imaging, 20X magnification, TAMRA channel (pseudo colored image). 
 
 
During the course of optimization of transfection of plasmid DNA using 
TurboFect reagent, it was found that transfection reagents can be used to deliver 
conjugates of oligo-aspartates into living cells. TurboFect is a cationic polymer, 
which forms complex with the negatively charged plasmid DNA and delivers 
the complex into the cells. We hypothesized that ARC compounds with nega-
tively charged oligo-aspartates (inhibitors of CK2α) would also be delivered 
into cells using TurboFect reagent.  
The cell-impermeable ARC-Photo probe, ARC-1505, labeled with TAMRA 
dye complexed with TurboFect and was successfully delivered into cells. ARC-
1505 was widely distributed all over cells. ARC-1505 was even transported into 
the nucleus of the cell. This is an easy way to deliver the ARC-probes with 
oligo-aspartates into cells. The activity of delivered compounds can be further 
monitored by their retarding effect on the phosphorylation of CK2α substrates 
(e.g., CDC37) using phospho-specific antibodies in Western blot analysis [84].  
This makes cellular delivery of oligo-aspartate comprising ARC-probes pos-
sible without any chemical modification. The technique can be used for 
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developing in vitro live cell-based assays for CK2 holoenzyme and CK2 inhib-
itors using TagRFP-fused CK2α and ARC-Photo probes. 
 
 
3. Determination of concentration of PIM kinases in  
cell lysate using ARC-Lum probes (Paper III and IV) 
PIM kinases are emerging as biomarkers for the early diagnosis of various types 
of cancer [23]. Therefore techniques are in need for determination of concentra-
tion of PIM2 in clinical samples. Previously, ARC-Lum probes have been suc-
cessfully used for measurement of the concentration of extracellular PKAc 
(ECPKA) in blood plasma samples [limit of quantification of the method was11 
pM (220 attomoles) of PKAc in the sample] of healthy persons and cancer 
patients [98]. 
Now the ARC-Lum probe ARC-3158 was successfully used for the determi-
nation of PIM2 kinase in cell lysates. ARC-3158 possesses KD value of 0.7 nM 
and has over 400-fold selectivity towards PIM2 over PKAc. However the pro-
duced TGL signal is comparable for PK/ARC-Lum complexes with both ki-
nases (Paper III, Figure 7). Thus at low PK concentration ARC-3158 generates 
a PIM-2-selective signal, but at higher concentration PKAc give rise to compa-
rable signal intensity.  
The PIM-selective ARC-Lum(Fluo) probe ARC-3158 was used to determine 
the concentration level of PIM2 in cell lysates (Paper IV, Figure 9). For this 
purpose, lysate of NIH/3T3 cells transfected with pCMV-PIM2 was produced. 
To avoid the non-specific signal that could arise from the off-target binding of 
the probe to other PKs in the cell lysate (e.g., PKAc), a PIM-selective inhibitor 
SGI-1776 was used as a PIM-selective inhibitor. In case of NIH/3T3 cells the 
endogenous expression of PKAc is high (Paper IV, Figure S3), therefore ARC-
3158 could bind to PKAc as well [155].  
The titration of ARC-3158 with the lysate of non-transfected NIH/3T3 cells 
produced a weak TGL signal, which resulted from the binding of ARC-3158 to 
other PKs, including PKAc. The addition of SGI-1776 to the samples did not 
reduce the TGL signal, this result indicated that there was no native PIM pre-
sent. Western blot analysis also revealed the absence of PIM2 protein in the 
lysate of native NIH/3T3 cells. The results demonstrate the applicability of 
ARC-Lum(Fluo) probes for the determination of the concentration of active 
PIM2 kinase in cell lysates . These techniques can be adapted for determining 
the level of PIM2 in lysates of cancerous cells or tissues. 
 
 
4. FRET between TagRFP-fused protein kinases and  
ARC-probes (Paper II, IV and unpublished data) 
In general, three types of intermolecular FRET are possible between lumino-
phores of ARC-Lum(Fluo) probes and TagRFP-fused PKs. 
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 The steady-state FRET (singlet–singlet FRET) between the fluorophore 
of TagRFP-fused PKs and fluorophores of ARC-Lum(Fluo) probes that 
incorporate fluorescent dyes emitting green light (e.g., Hilyte488, FITC) 
or red light (e.g., PF647, Atto647N) 
 The TR FRET (triplet–singlet FRET) between the luminophores of sul-
fur/selenium-containing ARC-Lum(–) probes and fluorophore of 
TagRFP-fused PKs 
 The TR FRET between luminophores of TagRFP-fused PKs and ARC-
Photo probes that are labeled with Lumi4Tb lanthanide cryptate 
 
 
The three types of intermolecular FRET-based sensors systems described here 
are specific between the luminophore of the ARC-probe and fluorophore of 
TagRFP-fused PK, thus the interaction of only genetically tagged PK and ARC-
probe is monitored. In case of an ARC-Lum(Fluo) probe, the intramolecular 
triplet–singlet FRET between the sulfur/selenium fragment and the fluorescent 
dye taking place, when the ARC-Lum(Fluo) probe is complexed with a PK. In 
this case, the PK is need not to be genetically tagged, thus the ARC-Lum(Fluo) 
probes have the selectivity issue, like other fluorescent probes of PKs.  
 
 
4.1. The intermolecular FRET between the  
ARC-Lum(–) probe and TagRFP-fused PKs 
After excitation of the selenium-comprising heteroaromatic fragment of ARC-
Lum(–) probes in complex with a PK with a flash of near-UV radiation at 330 
nm, part of energy is emitted from donor as fluorescence from the singlet ex-
cited state 1D* and part of energy as phosphorescence from the triplet excited 
state 3D*with microsecond-scale decay time (Figure 2). In case of ARC-
Lum(Fluo) probes energy from 3D* is also transferred non-radiatively by the 
FRET mechanism to the fluorophore attached to its peptidic part [if the absorp-
tion spectrum of the fluorophore at least partly overlaps with the phosphores-
cence emission spectrum of the donor]. In complex with a PK, FRET is also 
possible from ARC-Lum(–) probes to labels covalently attached to the protein if 
conditions for FRET between the luminophores are fulfilled, for example, the 
distance between the luminophores does not exceed two Förster distances of the 
luminophore pair. However, intramolecular FRET is usually more efficient as 
the distance between the phosphorescence donor and the acceptor fluorescent 
dye is shorter. 
The phosphorescence spectrum of ARC-3157/PK (PK = PIM2 or PKAc) 
complex with emission in the range of 450 to 600 nm (Figure 10) well overlaps 
with the absorption spectrum of the acceptor fluorescent protein TagRFP (Fig-
ure 8). The phosphorescence emission of ARC-3157/PK complex is very weak 
at the emission maximum of TagRFP (590 nm), thus the direct phosphorescence 
emission from the complex at 520 nm could be discriminated from the TagRFP-
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mediated signal at 590 nm resulting from the energy transfer from the 3D* state 
of ARC-3157/PK complex to singlet state of acceptor fluorophore TagRFP and 
emission from 1A* of TagRFP. In case of bicyclic ARC-Lum(–) probes, such as 
ARC-1138, the phosphorescence emission ranges from 400 nm to 750 nm with 
a wide peak at 550 nm to 650 nm (Figure 10) [97]. Therefore, the discrimination 
of the time-delayed phosphorescence emission from 3D* of ARC-1138/PK com-
plex and retarded fluorescence emission from 1A* of ARC-1138/TagRFP-PK 




Figure 10. The intermolecular FRET between ARC-Lum(–) probe and TagRFP-fused 
PKs. (A) The phosphorescence emission spectrum of ARC-Lum(–) probes, ARC-3157 
(green) and ARC-1138 (orange) in complex with PK (PKAc or PIM2). (B) The time-
delayed emission spectra of complex of ARC-3157 with TagRFP-PKAc (green) or 
TagRFP-PIM2 (red) in lysates of HeLa and NIH/3T3 cells, respectively.  
 
 
TGL emission spectra (excitation at 340 nm, delay 50 μs) of ARC-3157 in 
complexes with TagRFP-PKAc and TagRFP-PIM2 in diluted lysates were taken 
with Cytation 5 (Biotek) multi-mode reader (Figure 10). For the complex ARC-
3157/PIM2 or ARC-3157/PKAc, the delayed emission spectrum of the lysate 
possessed a maximum at 500 nm [155] and no emission was detectable at 590 
nm. The delayed emission spectrum of the complex of ARC-3157 with 
TagRFP-PIM2 and TagRFP-PKAc had two maxima, with peaks at 500 nm and 
590 nm. The latter peak is the result of intermolecular energy transfer from 3D* 
of ARC-3157 to the fluorophore of TagRFP-fused PKs and fluorescence emis-
sion from TagRFP, microsecond-scale decay being caused by slow prohibited 
energy transfer from 3D* to the singlet state of the acceptor. The obtained result 
is the first indication that a phosphorescent ARC-Lum(–) probe can be used 
together with a PK that is genetically tagged with a FP (for example, TagRFP-
fused PIM2) for construction of biosensor systems possessing photolumines-
cence with microsecond-scale decay time for analysis of PKs and their 
inhibitors. 
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Next, the direct triplet–singlet energy transfer between the luminophores of 
selenium-comprising fragment of ARC-3157 and TagRFP-fused PIM2 was 
compared in a displacement assay (Figure 11). The disruption of the complex 
ARC-3157/TagRFP-fused PIM2 by recombinant PIM2 led to the association of 
ARC-3157 with recombinant PIM2, thus the phosphorescence emission of 
ARC-3157 from 3D* state at 520 nm is recovered. As a result of the interruption 
of intermolecular FRET between the phosphorescent donor and acceptor 
TagRFP-fused PIM2, the microsecond-timescale emission from 1A* of TagRFP 




Figure 11. The intermolecular FRET between the selenium-comprising fragment of an 
ARC-Lum(–) probe and TagRFP-fused PIM2 (Paper IV, Figure 4). TGL intensity 
measured for disruption of complexes of ARC-3157 with PIM2-TagRFP and TagRFP-
PIM2 by recombinant PIM2. The luminescence intensity measured at (A) 520 nm and 
(B) 590 nm (B) and their ratio (C). (D) The normalized TGL intensity of ARC-3157/ 
PIM2-TagRFP complex measured at all the wavelengths.  
 
 
The displacement was monitored in wavelength range from 485 nm to 700 nm 
using different TRF modules of the plate reader (Figure 11D). The TGL signal 
measured at the phosphorescence emission range at 480 to 570 nm [where the 
energy from 3D* of selenium fragment is predominant], led to a binding curve, 
due to the association of ARC-3157 with recombinant PIM2. But the TGL sig-
nal measured at the fluorescence emission range of TagRFP at 580 nm to 700 nm 
[where emission from 1A* of TagRFP takes place] led to displacement curve 




4.1.1. Comparison of intermolecular and intramolecular FRET 
ARC-1451 is an ARC-Lum(Fluo) probe that derived from ARC-3157 through 
attachment of the fluorescent dye TAMRA. TAMRA possess photoluminescent 
properties (QY = 0.3, ε = 80,000 M-1cm-1 and similar spectral overlap with the 
phosphorescence emission of ARC-3157/PIM2 complex) that are similar to 
these of fluorescent protein TagRFP, thus this probe can be directly compared 
to ARC-3157/TagRFP-fused PIM2 complex.  
The luminescence lifetime of ARC-1451 in complex with PIM2 was  
47 ± 5 µs, this points to the intramolecular FRET efficiency of 40%. The 
luminescence lifetime ARC-3157/TagRFP-fused PIM2 complex was about 77 
µs, which corresponds to less than 10% intermolecular FRET efficiency. Also 
the TGL signal intensity of ARC-1451//PIM2 complex was 10–20-fold stronger 
than ARC-3157/TagRFP-fused PIM2 complex. This shows that the intra-
molecular FRET is more efficient as the distance between the phosphorescence 
donor and the acceptor fluorescent dye, in this case TAMRA, is shorter. 
Smaller FRET efficiency of the system with intermolecular positioning of 
luminophores, ARC-3157/TagRFP-fused PIM2, points to more distinct posi-
tioning of the luminophores in the complex. The improvement of FRET effi-
ciency could be achieved via increase of the Förster distance for the interacting 
luminophores, for example by increasing the phosphorescence QY of the donor 
phosphor, selenium-comprising aromatic system. Taking into consideration the 
feasibility of genetic introduction of fusion proteins into cells and efficient cel-
lular uptake of ARC-Lum probes, the intermolecular version of the assay (as 
exemplified through ARC-3157/TagRFP-fused PIM2 here) would have great 
potential for studies in living cells an additional dimension is given to the meas-
urements via the signal with microsecond-scale lifetime, mediated by the FP. 
This signal is easily separable from background fluorescence of cells and fluo-
rescent reagents, including FPs that do not participate in the interaction [96].  
 
 
4.2. The effect of positioning of the FP in  
TagRFP-fused PIM2 on the FRET efficiency 
The effect of positioning of TagRFP on FRET efficiency was studied using 
TagRFP-fused PIM2 and PIM specific ARC-Lum probes. Both N- and C-termi-
nally TagRFP-fused PIM2 proteins were expressed in NIH/3T3 cells and their 
concertation in cell lysate was sufficient for photoluminescence measurements. 
In case of PIM2-TagRFP protein, a 19 amino acid-long linker was used to fuse 
the proteins. In the other version, TagRFP-PIM2, the proteins were connected 
by a short, 7 amino acid-long linker. 
The triplet–singlet FRET between the luminophores of selenium-comprising 
aromatic system and TagRFP was discussed in the previous section. The TGL 
signal intensity of ARC-3157/TagRFP-PIM2 complex was approximately 2.5-
fold stronger than ARC-3157/PIM2-TagRFP complex (Figure 11B). Thus the 
intermolecular FRET from the phosphorescent donor, selenium-comprising 
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aromatic system to TagRFP is more efficient in case of TagRFP-PIM2 com-
pared to PIM2-TagRFP. This shows that in case of TagRFP-PIM2, the acceptor 
luminophore TagRFP is positioned more closely to the phosphorescence donor 
in the active site of PIM2 than in case of the other fusion protein. 
Then singlet–singlet FRET between the fluorophores of TagRFP-fused 
PIM2 and ARC-PF647 probes was compared. Two ARC-PF647 probes that 
structurally differed in length of the peptide part were chosen to compare the 
FRET efficiency from the donor fluorophore TagRFP. ARC-3158 comprised a 
hexa-arginine and ARC-3161 a nona-arginine peptide moiety. These spacers 
positioned the acceptor fluorescent dye PF647 at different distances from 
TagRFP. The affinity of the probes towards PIM2 was quite similar (KD values 
0.5–0.7 nM) [155]. FRET efficiency was calculated by measuring the change in 
the FI of donor fluorophores of TagRFP-fused PIM2, in the presence of PF647-
labeled ARC-3158 or ARC-3161.  
The FRET efficiency between the TagRFP donor fluorophore of PIM2-TagRFP 
and PF647 acceptor fluorescent dye of ARC-3158 in ARC-3158/PIM2-TagRFP 
complex was about 40% whereas that for the same fluorophores in ARC-
3158/TagRFP-PIM2 complex was about 30% (Paper IV, Figure 5). Thus the 
positioning of fluorophores is closer to each other in ARC-3158/PIM2-TagRFP 
complex. The application of a structurally similar luminescent probe ARC-3161, 
possessing more arginine residues in the peptide moiety in FRET studies resulted in 
well comparable results. The FRET efficiency was about 30% in ARC-3161/PIM2-
TagRFP complex and about 20% in ARC-3161/TagRFP-PIM2 complex. 
It is remarkable that singlet–singlet FRET efficiency between fluorophores 
of TagRFP-fused PIM2 with PF647 of ARC-3158 is more efficient in case of 
the complex ARC-3158/PIM2-TagRFP than in case of ARC-3158/PIM2-
TagRFP, that is contrasting the result of the triplet–singlet FRET efficiency 
between the luminophores of ARC-3157 and TagRFP-fused PIM2. This result 
points to different positioning of two interacting luminophores. In case of 
steady-state FRET assay the acceptor fluorophore of the ARC-Lum(Fluo) probe 
PF647 is out of the active site of PIM2 and more close to the fluorophore of 
TagRFP in complex ARC-3158/PIM2-TagRFP than in ARC-3158/PIM2-
TagRFP. Differently, the phosphor of ARC-3157 that is sitting in the ATP 
pocket of PIM2 is more close to TagRFP in complex ARC-3157/TagRFP-PIM2 
than in the complex ARC-3157/ PIM2-TagRFP. 
 
 
4.3. FRET-based assays in cell lysates using  
ARC-Photo probes and TagRFP-fused PKs  
The binding/displacement process between the complexes of ARC-
Lum(Fluo)/TagRFP-fused PK was monitored in either steady-state mode, TR 
mode or in both the modes in parallel. The application of the binding/ 
displacement assay with steady-state and/or TR FRET read-out enabled the 
determination of displacement IC50 values for inhibitors in cell lysates. 
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Figure 12. Schematic representation of interaction of an ARC-Lum(Fluo) probe labeled 
with PF647 dye and and TagRFP-fused PK. Steady-state and TR modes of FRET meas-
urement between the donor and acceptor luminophores are represented in the figure.  
 
 
Occurrence of FRET between PF647-labeled ARC-Photo probes, ARC-1182, 
ARC-1504, and ARC-3158, from one side and TagRFP-PKAc, TagRFP-CK2α 
and TagRFP-fused PIM2, from other side, was established. ARC-1182 and 
ARC-3158 are ARC-Lum(Fluo) probes that can be used for both the steady-
state and TR measurements, whereas ARC-1504 is a fluorescent probe that was 
used only in steady-state measurement of FRET.  
 
 
4.3.1. Steady-state measurement of FRET between  
ARC-PF647 probes and TagRFP-fused PKs 
The disruption of ARC-PF647/TagRFP-fused PKs complex by ATP-competi-
tive and substrate protein-competitive inhibitors was monitored by change in 
the emission intensities in the acceptor and donor channels (675 and 590 nm, 
respectively). The ratio of acceptor and donor emission intensities (FI675 nm/FI590 nm) 
was plotted against the concentration of inhibitor to obtain displacement curves. 
Better signal to background ratio was obtained upon converting the emission 
intensities of donor and acceptor channels into their ratio. At least 50% decrease 
in the value of FI ratio was obtained as the result of full displacement of the 
probe from the complex with TagRFP-fused PKs (Paper II, Figure 5 and Paper 
IV, Figure 6).  
The IC50 values determined in the FRET-based displacement assays were 
well correlated with the Kd values or Ki values of inhibitors measured using 
purified recombinant PKs in biochemical binding or inhibition assays (Paper II, 
Figure S12). The steady-state FRET system enabled the determination of IC50 
52 






















Figure 13. A displacement assay involving steady-state FRET measurement between 
fluorophores of TagRFP-fused CK2α and ARC-1504.  
 
 
In the example presented in Figure 13, structurally closely related inhibitors of 
CK2α were distinguished by FRET-based assay using the ARC-Photo probe, 
ARC-1504 and TagRFP-CK2α fusion protein in lysate of NIH/3T3 cells. The 
complex of ARC-1504/TagRFP-CK2α was disrupted by three inhibitors of 
CK2α, which were constructed by conjugating 4,5,6,7-tetrabromo-1H-benzim-
idazole (TBBi) moiety and carboxylate-comprising oligomers. The peptidic part 
of ARC-1852, ARC-1854 and ARC-1856 comprised 8 peptoidic residues with 
carboxylic acid groups, 8 L-aspartic acid residues or 8 D-aspartic acid residues, 
respectively. The compounds possessed Kd values of less than 0.1 nM. In spite 
of very high affinity of these inhibitors, the proposed system well differentiated 
the IC50 values of the compounds. 
The established steady-state FRET assay can be easily adapted for other PKs 
fused with TagRFP or other RFPs, such as mCherry and DsRed. To test the 
applicability of the proposed system to other RFPs, DsRed2 was used in the role 
of a FRET partner. Differently from monomeric TagRFP, DsRed2 is a tetra-
meric protein [117] possessing a high QY of 0.55 [120] and somewhat lower 
brightness than that of TagRFP [128]. FRET between fluorophores of N-termi-






ARC-1504 was established (Figure II Figure 7) and used for the determination 
of affinity of CK2α inhibitors. This shows that the method described in this 
study can be adapted to a wide variety of RFPs, regardless of their oligomeric 
nature. Still, the tetrameric nature of DsRed2 leads to the polymeric occurrence 
of the fused kinases that can lead to more complicated interpretation of optical 
effects and different binding kinetics of inhibitors.  
 
 
4.3.2. TR measurement of FRET between  
ARC-Lum(Fluo) probes and TagRFP-fused PKs 
In case of a displacement assays employing ARC-Lum(Fluo) probes, the bind-
ing/displacement can be monitored in parallel to steady-state FRET measure-
ments also with TR measurement. A problem in TGL-based assays employing 
ARC-Lum(Fluo) probes could be non-specific binding of the probes to other, 
non-target PKs present in cell lysate. Although the concentration of TagRFP-
fused PK in the lysate is high, the concentrations of other PKs and that of the 
endogenous untagged PK are unknown. But in case of the steady-state FRET 
measurement the obtained signal is pure in case of excess of the probe com-
pared to the total molar amount of PKs, meaning that FI measured is the result 
of the interaction of the donor fluorophore (TagRFP) fused to the PK and ac-
ceptor fluorophore conjugated to the ARC-Lum(Fluo). But still, the IC50 values 
calculated from FRET-based measurements were very well correlated with IC50 
values obtained in measurements with TGL read-out (Paper IV, Figure 6). In 
case of PIM2 fusions, both versions of the fusion protein were successfully used 
in the displacement assay to determine the IC50 values of inhibitors and the 
calculated Kd values were similar (Paper IV, Figure S9). Lysate containing 
overexpressed native PIM2 along with ARC-3158 was also used for the deter-
mination of IC50 values of the inhibitors and the calculated Kd values well cor-
related with the Kd values measured using recombinant PIM2 in other bio-
chemical assays (Paper IV, Figure S12).  
The application of bisubstrate ARC-Lum(Fluo) probes (that are displaced 
from the PK complex with both ATP-competitive and protein substrate-com-
petitive inhibitors [77]) in binding/displacement assays (Paper IV, Figure 6) led 
us to the discovery that an oligo(D-arginine) peptide, nona(D-arginine) amide 
[(D-Arg)9-NH2], binds to PIM kinases with high affinity. The peptide revealed 
Kd value of 150–200 nM with PKs PIM1 [91] and PIM2. (D-Arg)9-NH2 is very 
efficiently taken up by cells as an acknowledged arginine-rich transport peptide 
[156]. Its inhibitory effect towards PKs is not ATP-competitive, therefore its 
PIM inhibitory potential may be very high in living cells. Taking into account 
high (1–5 mM) concentration of ATP in cells and very low ATP Km value  
(Km = 4 μM) for PIM2 catalyzed reactions [157], at equal intracellular con-
centrations (D-Arg)9-NH2 inhibits PIM2 kinase as potently as ATP-competitive 
inhibitors possessing subnanomolar Ki values. Thus the application of (D-Arg)9-
NH2 as a transport peptide at usual 10 μM concentration may cause unexpected 
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cellular effects via inhibition of PIM2 and other PKs of the PIM family. Differ-
ently from some other transport peptides (e.g., TAT peptide) whose inhibitory 
potential towards PKs PKA and PKC has been also shown previously [158],  
(D-Arg)9-NH2 is proteolytically very stable and may retain its inhibitory effect 
for long time in cells and bodily fluids. Additionally, (D-Arg)9-NH2 is a potent 
inhibitor of a proprotein convertase furin (Ki = 1.3 nM) [159]. All these specific 
effects of (D-Arg)9-NH2 make the application of this peptide as a vehicle for the 
transport of a biologically active cargoes into cells (e.g.,[160]) a rather risky 
activity and the obtained results should be interpreted with care. 
In cell lysate-based displacement assays with the application of ARC-
Lum(Fluo) probes, 2 nM concentration of the probe was used together with 0.1 
to 0.5 µl of cell lysates. 100 µl of cell lysate was obtained by lysing transfected 
cells from a confluent well of a 6-well plate. Thus this lysate is sufficient for 
making a displacement assays in 200 to 1000 wells of a 384-well plate. The 
assay system enables the application of non-purified PKs for determination of 
affinity of inhibitors. Cell lysates containing the over-expressed TagRFP-fused 
PKs were used as the source of PK for the FRET-based assays. The developed 
assay system has the potential for testing of inhibitors of all PKs, provided that 
the expression of the PK as a fusion with TagRFP is successful and a red dye-
labeled probe is available that possesses sufficient affinity towards the PK. The 
cell lysate-based assay enables the application of non-purified PKs for determi-
nation of affinity of inhibitors. In this assay there is no need for capricious and 
expensive antibodies labeled with luminophores. A fresh batch of the target PK-
fused with TagRFP can be produced cheaply every week. Moreover, genes of 
different PKs can be easily introduced into plasmids instead of these of PKAc 
or CK2α thus adapting the assay for other PKs. 
 
 
4.3.3. Disruption of FRET in TagRFP-fused  
PK/ARC-Lum(Fluo) complex by recombinant PKs 
Different types of energy transfer take place in a FRET sensor that is comprised 
of a TagRFP-fused PK and an ARC-Lum(Fluo) probe. One is intermolecular 
steady-state fluorescence FRET (singlet–singlet) between the fluorophore of 
TagRFP and PF647. Secondly, the intramolecular and intermolecular TR FRET 
(triplet–singlet) between selenium-comprising phosphor of ARC-Lum probe to 
fluorophores of TagRFP and PF647, respectively. Thus a disruption of complex 
of ARC-Lum(Fluo) and TagRFP-fused PK by recombinant PK leads to the 
changes in different optical parameters. 
The complexes ARC-1182/TagRFP-PKAc and ARC-3158/TagRFP-fused 
PIM2 was disrupted by the addition of recombinant PKAc and PIM2 protein, 
respectively. The binding process was monitored in FA, FI and TGL measure-
ments.  
Re-association of ARC-1182 with un-tagged PKAc led to displacement of 
TagRFP-PKAc from the complex (Figure 14). FA read-out showed increase in 
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anisotropy values due to the additional binding of the free probe with recombi-
nant PK. The displacement led to the disruption of singlet–singlet FRET be-
tween donor TagRFP and acceptor PF647. The steady-state FRET measurement 
resulted in up to 50–60% decrease in FI ratio (Paper II, Figure S13). The TGL 
measurement at the emission maximum of PF647 and TagRFP led to a binding 
curve due to the association of probe to the recombinant PK, resulting from 





Figure 14. Disruption of complex ARC-1182/ TagRFP-PKAc by recombinant PKAc. 




Interestingly in case of ARC-3158/TagRFP-fused PIM2 complex, TGL meas-
urement taken at the fluorescence emission maximum of TagRFP at 590 nm 
resulted in a displacement curve (Paper IV, Figure 7). Displacement of ARC-
3158/TagRFP-fused PIM2 by PIM2 led to the termination of energy transfer 
from selenium-containing fragment to PF647. This points to the intermolecular 
energy transfer taking place from the selenium-comprising heteroaromatic sys-
tem (phosphorescence donor) to the acceptor fluorophore TagRFP even in the 
presence of another acceptor, PF647 which is located in closer proximity. The 
TGL intensity measured at the emission of the acceptor fluorophore PF647 at 
675 nm resulted in a binding curve, due to the association of ARC-3158 with 
56 
the recombinant PIM2. This led to efficient energy transfer from the selenium-
comprising phosphor of ARC-3158 to PF647 dye of ARC-3158. In parallel, the 
association of the selenium-comprising phosphor and TagRFP-fused PIM2 was 
disrupted that led to the displacement curve due to decrease in intermolecular 
FRET from selenium-comprising phosphor to TagRFP. These experiments 
show that the intramolecular energy transfer from the selenium-comprising 
phosphor to the fluorescent dye incorporated into ARC-Lum(Fluo) probes is not 
complete as there is still a partial energy intermolecular energy transfer to the 
TagRFP fused to PIM2. 
This effect could not be observed in case of ARC-1182/TagRFP-PKAc 
complex. The phosphorescence emission maximum of the preceding ARC-
Lum(–) probe, ARC-668 is at 550–650 nm (Figure 10) which overlaps with the 
fluorescence emission maximum of TagRFP. Hence the triplet–singlet emission 
of ARC-668/TagRFP-PKAc complex at 590 nm could not be discriminated 
from the phosphorescence emission of ARC-668/PKAc complex. In case of 
ARC-3157, the phosphorescence emission maximum is at 500 nm, hence 
emission at 590 nm, resulting from the triplet–singlet FRET between phosphor 
of ARC-3157 to TagRFP, could be very well discriminated from the 
phosphorescence of ARC-3157/PIM2 complex.  
 
 
4.3.4. TR measurement of FRET between  
ARC-Lumi4Tb probes and TagRFP-fused PKs  
The excitation spectrum of terbium cryptate Lumi4Tb has a maximum in near-
UV region of spectrum at 340 nm [161]. The emission spectrum of Lumi4Tb 
comprises four sharp peaks positioned at 490, 545, 590 and 620 nm [162], with 
distinct silent regions between the peaks (Figure 3). The emission spectrum of 
Lumi4Tb at least partially overlaps with absorption spectra of green, orange and 
red fluorophores, therefore all these dyes can be used as FRET partners (accep-
tor luminophores) with Lumi4Tb donor luminophore. Not only small organic 
fluorophores but also FPs such as different forms of GFP, YFP and RFP have 
been used as FRET partners for terbium chelates [163]. TR FRET assays for 
protein kinases have been previously reported using terbium and GFP-fused 
peptide substrates [164]. The application of Lumi4Tb in FRET measurements 
together with RFPs whose absorption spectra even better overlap with emission 
spectra of terbium cryptates than those of GFP or YFP has also been described 
[134]. As the absorption spectrum of TagRFP overlaps with the major emission 





Figure 15. Characterization of complex of ARC-Lumi4Tb and TagRFP-PKAc. (A) 
Determination of emission half-life of complies of ARC-1450 and TagRFP-PKAc 
(Paper II, Figure S9). (B) Determination of dissociation half-life of complex of ARC-
1450 and TagRFP-PKAc (Paper II, Figure S15). 
 
 
The emission spectrum of TagRFP is quite wide, possessing intense emission at 
570 and 610 nm, these regions well fit into the silent regions of the terbium 
emission spectrum. Therefore the emission of the acceptor luminophore 
TagRFP was measured using narrow band-pass filters 570(10) and 610(10) nm. 
The donor emission was measured at 490 and 545 nm. As Lumi4Tb lumino-
phore possesses very long luminescence lifetime (>2 ms) [161] the luminophore 
can be used for TR FRET measurements. In this case the donor luminophore is 
excited with a pulse of electromagnetic radiation (near-UV light, e.g., at 300–
370 nm using a xenon flash lamp or at 337 nm with a nitrogen laser) and the 
signal is measured after delay of 50–200 μs for 100–500 μs (acquisition time or 
gate time).  
The TR FRET-based sensors for PK inhibitors have been developed using 
TagRFP-fused PKs and Lumi4Tb labeled ARC-Photo probe ARC-1450. ARC-
1450 is derived by conjugating ARC-1411 with Lumi4Tb label. The FRET 
sensor, ARC-1450/TagRFP-PKAc, possessed long emission half-life (110–120 
µs) resulting from efficient energy transfer to TagRFP as determined from the 
decay curves (Figure 15A). As the parent compound ARC-1411 possesses slow 
dissociation kinetics, the dissociation half-life of ARC-1450 was determined. 
The dissociation half-life of the ARC-1450/TagRFP-PKAc complex was found 
to be 15 min (Figure 15B). After the characterization of FRET between these 
two partners, the FRET system was successfully used for the characterization of 
inhibitors of PKs (Paper II, Figure 6 and Paper IV, Figure 8). An incubation 
time of 60–120 min was used to achieve the complete disruption of the FRET 
complex (Paper II, Figure S16) by the inhibitors of PKAc. The application of 
the TagRFP-fused PKs and ARC-1450 was demonstrated in displacement as-
says for the characterization of inhibitors of PKAc and PIM2 kinase. The ratio 
of luminescence intensity calculated from all emission channels had sufficient 
measurement window and high signal to background ratio. 
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SUMMARY 
In this study, a combination of chemical and genetic approaches was used for 
construction of sensor systems for analysis of protein kinases. 
Synthetic ARC-Lum probes possessing unique photoluminescence proper-
ties were developed for protein kinases PKAc, CK2α and PIM kinases. Bisub-
strate inhibitor approach was applied for achieving high affinity and selectivity 
of ARC-inhibitors towards the target protein kinases. Various heteroaromatic 
fragments such as benzoselenadiazole and benzoselenopyrimidine were intro-
duced into ARC-compounds for construction of photoluminescent ARC-
Lum(Fluo) probes.  
To develop FRET-based assays, protein kinases (PKAc, CK2α, and PIM ki-
nases) were overexpressed in mammalian cells as fusions with red fluorescent 
protein, TagRFP. Assays were developed for measurements in cell lysates by 
combining TagRFP-fused kinases and ARC-probes that were labeled with com-
plementary luminophores, such as PromoFluor-647 and Lumi4Tb. Photolumi-
nescence assays using both steady-state and time-resolved read-outs were de-
veloped. Application of Lumi4Tb-labeled ARC-probes enabled to perform these 
assays with very high signal-to-noise ratio. 
The mechanism of energy transfer between interacting luminophores was 
extensively studied in this work. The protein-induced long-lifetime lumines-
cence property of ARC-Lum(Fluo) probes is based on intramolecular energy 
transfer from the excited triplet state of the selenium-comprising heteroaromatic 
system to the fluorescent dye, leading to long-lived (τ = 50–120 μs) emission in 
the region of the fluorescence emission spectrum of the dye. Suitability of 
different dyes for efficient FRET-based ARC-Lum(Fluo) was determined.  
Considering the emerging importance of kinases of the PIM family (PIM1, 
PIM2 and PIM3) as potential drug targets as well as cancer biomarkers, the 
development of research tools for these kinases has especially great importance. 
Therefore the applicability of different ARC-Lum probes as FRET partners for 
PIM2-fused with TagRFP was determined. Fusions of PIM2 with N- or C-ter-
minally positioned fluorescent proteins (TagRFP-PIM2 and PIM2-TagRFP, 
respectively) were expressed in mammalian cells. This study systematically 
evaluated the dependence of efficiency of FRET on structure of the probe and 
architecture of the fusion protein. The study revealed that in case of same inter-
acting partners (the probe and the protein kinase) measurement of FRET effi-
ciency according to different energy transfer mechanisms (including triplet–
singlet and singlet–singlet energy transfer) may give complementary infor-
mation for structural studies and construction of novel sensor systems for kinase 
research. 
The study demonstrated for the first time that phosphorescence of selenium-
comprising aromatic systems can be transferred by FRET mechanism to fluo-
rescent labels of genetically tagged protein kinases. This opens a new possibil-
ity for the application of cell plasma membrane-permeable ARC-Lum probes in 
combination with genetically modified kinases for construction of sensor 
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systems for monitoring and mapping of protein kinase activity in living cells. 
Considering the long-lived (microsecond-scale) photoluminescence of the novel 
sensor systems, such sensors produce signals that are well separable from auto-
fluorescence of cells and chemical compounds. It follows that the measurements 
can be performed with high signal-to-noise ratio and good three-dimensional 
resolution using time-gated luminescence microscopy techniques.  
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SUMMARY IN ESTONIAN 
Keemiliste ja geneetiliste meetodite ühitamine 
proteiinkinaaside fotoluminestsentsanalüüsiks 
Doktoritöös kasutati geneetilisi ja keemilisi meetodeid sensorsüsteemide 
loomiseks proteiinkinaaside analüüsiks. 
Proteiinkinaasid katalüüsivad valkude fosforüülimist, see on oluline reakt-
sioon valkude modifitseerimisel, mille kaudu reguleeritakse valkude aktiivsust 
rakkudes. Valkude fosforüülimine võimaldab suurendada proteoomi mitmekesi-
sust, seeläbi mõjutatakse rakkude normaalset ja patoloogilist toimimist. Val-
kude fosforüülimistasakaalude nihkumine PKde häiritud aktiivsuse tõttu on 
paljude raskete haiguste (vähktõve erinevad vormid, diabeet jne) põhjuseks või 
märguandeks nende tekkimise kohta. Sellest tuleneval on proteiinkinaasid olnud 
21. sajandi olulisteks ravimiarenduse sihtmärkideks. Viimase 15 aasta jooksul 
on 30 proteiinkinaaside inhibiitorit jõudnud vähiravimitena haiglatesse. 
Lisaks olulisele rollile ravimiarenduses on proteiinkinaasid tähtsad bio-
markerid vähktõve erinevate vormide ning teistele haiguste tuvastamisel. Sellest 
tuleneb ka suur nõudmine analüüsimeetodite järele, mis võimaldaksid määrata 
kinaaside kontsentratsiooni ja aktiivsust kliinilistes proovides, näiteks keha-
vedelikes ja biopsiaproovides.  
Viimasel aastakümnel on mõistetud, et just kahe uurimisala, sünteetilise 
keemia ja valkude konstrueerimise geneetiliste meetodite kooskasutamine on 
vajalik uudsete omadustega molekulide ja nende komplekside konstrueeri-
miseks. Need struktuurid lisaksid uudseid võimalusi biomeditsiiniliste uuringute 
läbiviimiseks, ravimiarenduseks ning haiguste tuvastamiseks.  
Käesolevas töös ühitati keemilised ja geneetilised meetodid selleks, et välja 
arendada uudsed sensorsüsteemid PKde ja nend inhibiitoride uurimiseks. Ühelt 
poolt toodeti imetajate rakkudes mitmete proteiinkinaaside (PKAc, CK2α, and 
PIM-kinaasid) liitvalke fluorestseeruvate valkudega. Teisalt konstrueeriti ARC-
inhibiitoritest lähtuvalt uudsete luminestsentsomadustega kõrge afiinsusega 
sondid kinaasidede jaoks [ARC-Lum(Fluo)-sondid].  
Seoses PIM-kinaaside (PIM1, PIM2 ja PIM3) olulise tähtsusega nii ravim-
arenduse sihtmärkidena kui ka vähktõve biomarkeritena, on abivahendite välja-
töötamine nende kinaaside uurimiseks suure praktilise väärtusega. PIM2 
liitvalke punase fluorestseeruva valguga (TagRFP) ekspresseeriti imetajate 
rakkudes kahel erineval kujul (TagRFP-PIM2 ja PIM2-TagRFP). Töös näidati, 
need erineva märgise paigutusega liitvalgud omavad kompleksis ARC-
Lum(Fluo)-sondidega erinevaid luminestsentsomadusi, mis tuleneb erinevast 
Försteri-tüüpi energiaülekandest vastasmõjus olevate luminofooride vahel. Töös 
näidati esmakordselt, et kompleksis on võimalik energiaülekanne seleeni-sisal-
dava aromaatse süsteemi ergastatud tripletest olekust kinaasiga seotud fluo-
restseeruvale valgule, mille tulemusena fluorestsentsvärvilt kiiratav valgus on 
küll värvile omase kiirgusspektriga, kuid enam kui 10000 korda pikema 
elueaga. 
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See tulemus loob eelduse rakusiseste sensorsüsteemide loomiseks raku 
plasmamembraani läbivate ARC-Lum(Fluo)-sondide ja rakkudes ekspres-
seeritud proteiinkinaasi ja TagRFP liitvalkude baasil, mis võimaldaks kaar-
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